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ABSTRACT 
 
Polyelectrolytes have emerged as a versatile, simple and promising tool to 
deliver therapeutic payloads. Their ability to form complexes with oppositely charged 
polymers or biomacromolecules has led to various applications in the pharmaceutical 
and biotechnology industries. In this thesis, three different polyelectrolyte delivery 
systems have been developed and explored for potential uses in gene and protein 
delivery. 
Polyvinylamine (PVAm) nanogels with different amounts of surface charge 
and degradability were used to systematically inspect gene transfection efficiency and 
cytotoxicity. Transfection efficiency of non-degradable nanogels increased with 
increasing amounts of positive charge. Intriguingly, acid-labile nanogels bearing low 
charge showed sustained gene transfection and low cytotoxicity. An intricate balance 
between transfection efficiency and cytotoxicity is crucial for gene vectors. These 
results led to an exploration of less toxic, small polycations. 
Historically, polyplexes using small polycationic peptides such as TAT have 
shown relatively poor gene transfection, however, previous studies in our group 
showed that the transfection efficiency could be enhanced by condensing these large 
polyplexes using calcium. In this thesis, the LABL peptide targeting intercellular cell-
adhesion molecule-1 (ICAM-1) was conjugated to TAT peptide using a polyethylene 
glycol (PEG) spacer. Though the transfection efficiency of TAT polyplexes was 
reduced by PEGylation, TAT complexes targeting ICAM-1 were able to restore high 
levels of gene transfection. Thus, targeted TAT polyplexes offer promise for gene 
delivery to sites of injury or inflammation. Next, other PEGylation strategies using 
polyelectrolytes were explored. 
iv 
 Repifermin, a truncated version of fibroblast growth factor-10 (FGF-10) also 
known as keratinocyte growth factor-2 (KGF-2), is a heparin-binding protein with 
potent regenerative properties. The protein unfolds and aggregates at relatively low 
temperature (~37 oC). The thermal stability of several FGFs was enhanced by 
electrostatic interactions with polyanions. PEG was grafted to the polyanions pentosan 
polysulfate (PPS) and dextran sulfate (DS). The potential uses of polyanion 
conjugates were explored using a variety of spectroscopic and calorimetric methods, 
and dynamic light scattering. PPS-PEG and DS-PEG conjugates were able to stabilize 
KGF-2 by increasing the melting temperature of the protein complexes. Though there 
are several parameters that could be optimized to improve the protein structure upon 
binding, polyanion-PEG conjugates, however, are encouraging reagents that can 
improve the thermal stability of heparin-binding proteins via electrostatic PEGylation.  
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Polyelectrolytes as therapeutic delivery systems 
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1.1 Introduction 
Many of the pharmacological and therapeutic properties of drugs can be 
improved through the use of drug delivery systems (DDSs) such as lipid- and 
polymer-based nanoparticles. DDSs are often designed to alter pharmacokinetics, 
biodistribution, or to serve as drug reservoirs. Polymers have been used intensively in 
DDSs and recently have emerged as an essential component of novel therapeutics. 
These therapeutics include macromolecular drugs, polymer-drug and polymer-protein 
conjugates, and polymeric drug delivery systems such as polymeric micelles and 
polycation complexes with DNA or RNA (polyplexes).  
Several improvements have been reported when using polymers in DDSs. 
First, conjugation of polyethylene glycol (PEG) has resulted in the improved stability 
and pharmacokinetic properties of many therapeutic proteins. Several PEGylated 
protein products are commercially available. For example, PEGylated asparaginase 
(Onspar), PEGylated adenosine deamidase (Adagen) and PEGylated interferon 
(PEG-Intron and PEG-Asys).1 Second, conjugation of low-molecular weight 
anticancer drugs to polymers has improved the therapeutic index of several anticancer 
drugs. Some anticancer drug conjugates are in clinical trials. For example, 
polyglutamate-paclitaxel (CT-2103; XYOTAX), N-(2-hydroxypropyl) 
methacrylamide (HPMA)-doxorubicin (PK1; FCE28068) and HPMA-doxorubicin-
galactosamine (PK2; FCE28069).2 Other novel polymer-based DDSs are well-defined 
multivalent and dendritic polymers such as the microbicide VivaGel, a dendritic 
polyanion that can potentially reduce or prevent transmission of HIV.3  
There are several approaches to incorporate therapeutics to and/or into 
polymers including covalent conjugation, entrapment or encapsulation, and 
electrostatic complexation. Covalent conjugation usually involves harsh chemicals 
3 
and/or organic solvents and often, a reduction in biological activity has been 
reported.1 Meanwhile, polymerization reactions can require multiple preparation and 
purification steps. As a result, this thesis focuses on electrostatic interactions between 
oppositely charged biomacromolecules such as nucleic acids or model proteins and 
polyelectrolytes, to explore various polyelectrolyte-based DDSs.  
1.2 Background and general properties 
Polyelectrolytes are polymers carrying ionizable groups along the polymer 
chain. Polyelectrolytes may be anionic, cationic or amphiphilic and they may be 
synthetic or natural. Examples of polyelectrolytes include poly(acrylic acid), 
poly(methacrylic acid), poly(vinyl amine), poly(4-vinyl pyridine), and many 
biological molecules such as polypeptides, proteins, nucleic acids, and 
polysaccharides. Polyelectrolytes are used in a variety of industries such as 
papermaking, food processing, medicine and pharmaceuticals, water purification, oil 
field exploration, and cosmetic formulation. This chapter will briefly overview 
polyelectrolytes, classifications, general properties, and polyelectrolyte-
polyelectrolyte and polyelectrolyte-surfactant interactions, then focus will shift to 
biomedical applications of polyelectrolytes. 
1.2.1 Classification of polyelectrolytes  
Polyelectrolytes are available in a wide range of chemistries, molecular 
weights and charge densities. For biomedical applications, certain polyelectrolytes 
reviewed here have the potential to be translated to the clinic such as biodegradable 
synthetic polyelectrolytes or natural polyelectrolytes.  
1.2.1.1 Synthetic polyelectrolytes 
Polyelectrolytes can be synthesized by polymerization of ionized monomers, 
incorporating ionizable groups into a polymer chain, or by chemical modification of 
4 
existing polymers (Table 1.1). These methods have been reviewed extensively 
elsewhere (see Scranton et al. 4, Jiang et al., 5 and Bohrisch et al. 6). Generally, 
polymerization is more prevalent since the properties of final products can be 
controlled easily. However, the method of choice depends upon the type of added 
functional groups and the nature of parent polymers.  
For the first method, polymerization of ionizable monomers, polyelectrolytes 
are commonly synthesized by free-radical polymerization of monomers containing a 
carbon-carbon double bond. Crosslinked polymers may be produced by including a 
small amount of a crosslinking agent. Step-growth polymerization reactions may be 
used to synthesize polyelectrolytes, but this method is less common.  This reaction is 
a type of polymerization in which monomers react to form dimers, trimers, longer 
oligomers and eventually long chain polymers and initiators or terminators are not 
usually required.  
 The second method employs post-polymerization modifications of nonionic 
polymers. Sulfonation can produce anionic polyelectrolytes containing sulfonic acid 
groups. Addition or substitution reactions may be used to produce polyelectrolytes. In 
addition, hydrolysis or oxidation of labile bonds may also be used to functionalize 
nonionic polymers. 
Both of these methods have been successfully employed to create 
homopolymer or random copolymer polyelectrolytes. In addition, amphiphilic block 
copolymers which contain both anionic and cationic blocks can be synthesized by 
using free-radical polymerization, by modifying one block of a block copolymer, or 
by coupling two blocks that were synthesized a priori. More advanced polyelectrolyte 
architectures such as branched, conjugated or star-shape polyelectrolytes have been 
5 
widely studied to achieve desired properties. Several authors have reported these 
methods elsewhere. 5,7 
Table 1.1. Representative synthetic polyelectrolytes 
Name Structure 
CH2CH
COOH
n
CH2C
COOH
n
CH2CHNH
n
CH2CH
NH2
n
CH2CH
n
CH3
H
N
Poly(acrylic acid)
Poly(methacrylic acid)
Poly(ethylenimine)
Poly(vinylamine)
Poly(4-vinylpyridine)
 
_____________________________________________________________________ 
1.2.1.2 Natural polyelectrolytes 
 Among polymeric materials, natural polymers are ideal candidates for 
therapeutic formulation, since they are generally non-cytotoxic even at high 
6 
concentrations.8 They also often contain reactive sites that are amendable to 
conjugation, crosslinking and other modifications. Natural polyelectrolytes have 
emerged as therapeutics in molecular medicines (e.g. proteins, nucleic acids, and 
peptides) or as essential components of carriers or platforms in drug and gene 
delivery, vaccination, and tissue engineering (e.g. polysaccharides and polypeptides). 
For example, chitosan has been successful in oral and nasal delivery due to the 
mucoadhesive property. Collagen, gelatin, chitosan, alginate, and their derivatives 
have been extensively studied in gene therapy. 
 Nucleic acids  
Nucleic acids including deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA) have emerged as promising therapeutics in cancers, cardiovascular, 
inflammatory, and infectious diseases as well as organ transplantation.9 Nucleic acids 
can be synthesized via polymerase chain reaction (PCR) or solid phase synthesis. 
Nucleic acid-based therapeutics include plasmids containing transgenes for gene 
therapy and vaccines, oligonucleotides for antisense and antigene applications, 
ribozymes, DNAymes, aptamers, small interfering RNAs (siRNAs) and others. 
Plasmids are high molecular weight, double-stranded DNAs containing transgenes, 
which encode specific proteins.10 Oligonucleotides are short single-stranded segments 
of DNA that can selectively inhibit the expression of a single protein after being 
internalized.11 Ribozymes are RNA molecules which can cleave mRNA molecules in 
a sequence specific manner.12 DNAzymes are analogs of ribozymes which have 
greater biological stability.13 SiRNAs are short doublestranded RNAs with typically 
21-23 nucleotides that are complementary to the targeted mRNA intended for 
knockdown.14-15 
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Poly(amino acid)s or polypeptides 
Amino acid-based polymers have received much attention due to their 
biocompatibility and biodegradability and the accuracy of their synthesis. Poly(amino 
acid)s can be biosynthesized from microorganisms or chemically synthesized. Some 
of these polymers have unique properties and functions derived from the amino acid 
moiety. For example, poly(glutamic acid) is a poly(amino acid) with carboxyl groups 
on the side chain which allow conjugation with several chemotherapeutic agents such 
as doxorubicin, daunorubicin, mephalan, paclitaxel, and camptothecin.16 In addition, 
poly(L-lysine) and poly(arginine) have been widely used as non-viral carriers. These 
poly(amino acid)s are protonated in a physiological environment and are able to form 
complexes with negatively charged DNA. Some poly(amino acid)s such as TAT 
peptide have the ability to cross cellular membranes allowing the intracellular 
delivery of various molecules ranging from low molecular weight drugs to nanosized 
particles.17 
Polysaccharides  
Polysaccharides are polymers formed from repeating monosaccharides or 
disaccharides which are linked together by glycosidic bonds. Polysaccharides are 
often heterogenous, containing slight modifications of repeating units. 
Polysaccharides can be produced via microbial fermentation, animal and plant 
extraction. Polysaccharides have emerged as a class of biomaterials with enormous 
potential applications including protein interactions, cell and tissue engineering, 
vaccine delivery, and cancer treatment.18-19  Some selected natural polysaccharides 
which are of interest in this thesis are listed below.  
Chitin and chitosan: Chitin is a major component of crustacean shells such as 
crab, shrimp and crawfish shells and is a byproduct of the shell-fish industry. It is a 
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copolymer of β-1,4 linked D-glucosamine and N-acetyl D-glucosamine. Chitosan is 
modified from chitin, by partial deacetylation of the N-acetyl D-glucosamine residues. 
Chitosan is insoluble in water, but soluble in weak organic solutions such as acetic 
acid and formic acid.20 
 Alginate: Alginate is a linear anionic polysaccharide. It is a block copolymer 
of β-1,4 linked D-manuronic acid (M) and -1,4 linked L-guluronic acid (G) residues, 
produced by algae. The monomers can be arranged in consecutive MM blocks, 
consecutive GG blocks, alternating MG blocks or randomly organized blocks.21 It has 
abundant hydroxyl and carboxyl groups (one carboxylic group per saccharide unit). 
Alginate absorbs water quickly. 
 Dextran and dextran sulfate: Dextran is a complex, branched glucan in which 
the straight chain consists of α-1,6 glycosidic linkages of glucopyranose units and 
branches begin from α-1,3 linkages. Dextran can be synthesized either chemically or 
by certain lactic-acid bacteria from sucrose.22 Dextran sulfate is a negatively charged 
polymer that can be synthesized by sulfonation of dextran.23 It typically contains 
approximately 17% sulfur, which is equivalent to approximately 2.3 sulfate groups 
per glucosyl residue, although the degree of sulfonation can vary. 
 Chondroitin sulfate: Chondroitin sulfate is a sulfated glycosaminoglycan 
(GAG) composed of a chain of alternating sugars N-acetylgalactosamine (GalNAc) 
and glucuronic acid (GlcA). Each sugar residue can be sulfated in variable positions 
and quantities. For example, chondroitin-4-sulfate is sulfated at carbon 4 of GalNAc 
sugar, chondroitin-6-sulfate is sulfated at carbon 6 of GalNAc sugar, chondroitin-2,6-
sulfate is sulfated at carbon 2 of GlcA and 6 of GalNAc sugar and chondroitin-4,6-
sulfate is sulfated at carbon 4 and 6 of GalNAc sugar. 
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 Heparin and heparan sulfate: Heparin and heparan sulfate are linear 
polysaccharides which have similar structures, but heparan sulfate is less sulfated. 
Heparin and heparan sulfate consist of variably sulfated repeating disaccharide units 
that can be combined into a large variety of different sequences. The most common 
disaccharide unit is composed of a glucoronic acid (GlcA), N-acetylglucosamine 
(GlcNAc), 2-O-sulfated iduronic acid and 6-O-sulfated and N-sulfated glucosamine.  
 Sucrose octasulfate: Sucrose octasulfate (SOS) is a sulfated disaccharide. 
Sucrose octasulfate was found to mimic heparin action by supporting fibroblast 
growth factor (FGF)-induced neoangiogenesis and cell proliferation in vitro.24-26 SOS 
is also a precursor of Sucrafate, an anti-ulcer drug that mediates its action through 
interaction with FGFs.27-28 
Table 1.2. Representative natural polyelectrolytes 
Name Structure 
Nucleic acids:  
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Name Structure 
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Name Structure 
Polysaccharides:
 
Dextran sulfate
O
O
O
O3S
O
O3S
SO3
O
SO3 O
O3S
O
O3S
SO3
HO
O
O3S
O
O3S
SO3
 
 
 
 
13 
Name Structure 
Chondroitin-4-sulfate O O
O
O
O
HO
OH NH
OH
O
O
O3SO
 
Chondroitin-6-sulfate O O
O
O
O
HO
OH NH
OSO3
O
O
HO
 
 
Sucrose octasulfate
O
O
O3SO
OSO3
OSO3
OH
O3SO
O3SO
O3SO
OSO3
O3SO
 
14 
1.2.2 Polyelectrolyte properties  
In solution, polyelectrolytes exhibit interesting behavior different from that of 
uncharged polymers. For example, the conformation of polyelectrolytes depends on 
the degree of ionization. An uncharged linear polymer is often found in a “random 
coil” conformation in solution (Figure 1.1A). The charges on a linear polyelectrolyte 
chain will repel each other, which can cause the chain to expand to a “rigid-rod-like” 
conformation (Figure 1.1B).29  
 
 
 
 
Figure 1.1. (A) An uncharged polymer molecule in a random coil shape (B) an 
anionic polyelectrolyte in salt-free solution.  
The ionic groups of a polyelectrolyte may interact with one another or with 
mobile charges in the solution. Therefore, solution properties of polyelectrolytes such 
as viscosity and light scattering depend strongly on the degree of ionization (which 
depends on their structures and the pH of the solution), polyelectrolyte concentration 
and ionic strength. For example, under ideal conditions the viscosity of 
polyelectrolyte solutions is proportional to the square root of polymer concentration 
(Fouss law), whereas the viscosity of uncharged polymers is proportional to the 
polymer concentration.30 Additionally, the osmotic pressure of polyelectrolytes in 
salt-free solutions can be several orders of magnitude higher than the osmotic pressure 
of neutral polymer at similar polymer concentrations.31 Medium conditions such as 
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pH also have an effect on polyelectrolyte viscosity. For example, at low pH, aqueous 
solution of a weak acid polyelectrolyte will exhibit a relatively low viscosity when the 
polymer is in its neutral form and a higher viscosity in its ionized form at intermediate 
pH.  If salt is added to the solution, the polyelectrolyte chain will collapse due to 
screening effects and this phenomenon leads to a decrease in the viscosity. In 
summary, polyelectrolytes generally exhibit higher water solubility, expanded 
hydrated dimensions and a higher sensitivity to ionic strength and pH compared to 
nonionic polymers.  
Polyelectrolytes in solution can form stable polyelectrolyte complexes (PECs). 
PECs can be formed using either oppositely charged polyelectrolytes, or a 
polyelectrolyte-surfactant pair. The PEC formation process is usually entropically 
driven by the release of counter ions and water from the hydrated polyelectrolyte 
molecules.32-33 However, other forces such as hydrogen bonding, hydrophobic 
interactions, van der Waals forces or dipole-charge transfer may be involved in the 
formation of PECs.34 Even though the formations of polyelectrolyte and 
polyelectrolyte-surfactant complexes are similar, their solid-state structures are 
different. Polyelectrolyte-surfactant complexes commonly have highly ordered solid 
state structures such as frozen liquid crystals, whereas, PECs show somewhat fuzzy 
structures, for example, ladder and scrambled-eggs structures. Polyelectrolyte-
surfactant complexes have order because of coorperative binding of surfactant 
molecules onto polyelectrolyte chains and the amphiphilicity of surfactant 
molecules.34   
Synthetic polyelectrolytes are generally used in PEC formation studies since 
key parameters such as molecular weight and charge density can be precisely 
controlled. PEC formation leads to different structures, depending on the 
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characteristics of polyelectrolytes used, mixing regime, and media conditions such as 
ionic strength and pH.34-35   Historically, mechanisms of PEC formation were studied 
in the 1970s by Tasuchida and Kabanov.34-36 In early studies, PEC formation of strong 
polyelectrolytes with a high charge density at a stoichiometric charge ratio (1:1) led to 
precipitated PECs which were insoluble in all common solvents. PECs formed at non-
stoichiometric mixing ratios under certain conditions such as solutions < 1x10-3 g/mL 
did not precipitate and resulted in a stable dispersion of PEC particles.36 In addition, 
an appropriate amount of salt in the solution was found to shift kinetically formed 
complexes toward the thermodynamically favored component since salt weakens the 
electrostatic interaction and enables rearrangement.37 The role of salt in the formation 
of ‘soluble’ PECs (stable suspensions) was extensively studied in the 1990s.33,38-40 In 
general, particle flocculation was reduced at low ionic strength. Further increasing 
ionic strength at first led to a shrinking of PECs due to charge shielding by the 
electrolyte. When a critical ionic strength was exceeded, PECs were again 
precipitating. At even higher ionic strength, the precipitate dissolved and both 
components existed as free polyelectrolyte chains in solution. 
To date, PEC structures may be categorized into two main types according to 
the structure of constituent polyelectrolytes. First, water-soluble PECs are formed 
using weak polyelectrolytes having very different molecular weights and mixed in 
non-stoichiometric ratios.38 These PECs usually consist of a long host molecule 
sequentially bound with shorter, oppositely charged guest molecules according to the 
ladder model. Second, insoluble and aggregated PECs can form using polyelectrolytes 
having a high charge density and/or relatively high molecular weights, especially 
when mixed at or near a 1:1 charge ratio. These structures follow the scramble-eggs 
model.39 This PEC formation at high concentration (> 1x10-2 g/mL) will tend towards 
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flocculation whatever the mixing ratio, but the formation at very low concentration (< 
1x10-4 g/mL) and non-stoichiometric mixing ratios will give stable suspensions.34,39  
Several groups have studied the formation of water-soluble PECs at different 
mixing ratios, buffers and pH in order to examine colloidal stability and degree of 
hydration and to develop optimized nanoparticles for biomedical applications. In 
general, the formation of stable PECs requires the non-stoichiometric mixing of two 
constituent polyelectrolyte solutions. The constituent solutions can be mixed by slow 
titration of the default polymer into the polymer in excess or by rapid addition. 
Variations of particle size due to charge mixing ratios were found to be similar for 
both modes of addition, but rapid addition was less sensitive to order of mixing.40 
Additionally, rapid addition may result in more stable particles than slow titration 
when the charge mixing ratios are close to 1:1.40  
PECs tend to have very broad size distributions and not all constituent 
polyelectrolytes are consumed in the formation of stable PECs.41-42 Polymer charge 
density is an important factor in PEC stability, but, in the presence of salt, charge 
density by itself can not control the structure and stability of PECs.43 Chain length (or 
molecular weight) and composition also influence the PEC particle size and colloidal 
stability. Schatz et al. and Drogoz et al. have studied PEC formation using different 
molecular weights of cationic chitosan and anionic dextran sulfate mixed via 
dropwise addition. Two situations could be identified (Figures 1.2).40,42 First, when 
the polyelectrolytes in excess have high molecular weight and could act as host and 
accommodate several of shorter guest polyelectrolyte molecules, stable PECs 
consisting of a hydrophobic core and a large hydrophilic corona were formed. 
Addition of short guest polyelectrolytes led to a limited size reduction. Second, when 
the polyelectrolytes in excess are smaller than the titrant, the outcome depended on 
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the capacity of the excess polyelectrolytes for charge neutralization. If the excess 
polyelectrolytes were too small and weakly charged, flocculation occurred. If the 
excess polyelectrolytes were not too small, dense particles stabilized by unpaired 
charges was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. A representative scheme of PEC formation when the two constituent 
polyelectrolytes have very different molecular weights.33  
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1. 3 Biomedical applications of polyelectrolytes 
Polyelectrolytes can be used to deliver a number of therapeutics ranging from 
small molecule drugs to macromolecules. Polyelectrolyte complexes offer several 
potential benefits such as stabilizing therapeutics during formulation and storage, 
targeting therapeutics to desired sites of action, releasing therapeutics with 
controllable kinetics, and minimizing toxicity and side effects of therapeutics. 
Moreover, some polyelectrolyte properties such as swelling can be controlled by 
external stimuli, which can enable environmentally responsive delivery systems. In 
particular, for fragile therapeutics such as proteins and nucleic acids, nanoparticle 
synthesis using polymerization or solvent removal techniques (e.g. precipitation) may 
expose the therapeutic to harsh temperature and/or solvent conditions. In contrast, 
nanoparticle formation by polyelectrolyte complexation can be done in aqueous 
solutions at or near physiological pH and ionic strength, and at room temperature or 
lower. Such conditions can preserve conformation and biological activity of 
therapeutics. As a result, development of polyelectrolyte nanoparticle-based delivery 
systems for proteins, nucleic acids, and vaccines has been widely explored. 
1.3.1 Drug and nucleic acid delivery  
Amphotericin B (AmB) is an antifungal agent that has poor oral 
bioavailability due to its low solubility. There are two forms of intravenous 
preparations available; liposomal and lipid complex formulations. The lipid complex 
formulation (Ampholip®) has serious nephrotoxicity. Liposomal formulations 
(AmBisome® and Fungisome®) have reduced toxicity, but are quite expensive. 
Therefore, developing safer and more affordable formulations is desirable. 
Tiyaboonchai and others have developed AmB-loaded polyethylenimine (PEI)-
dextran sulfate (DS) PEC nanoparticles. The AmB-loaded nanoparticles showed high 
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drug loading efficiency, low cytotoxicity and high efficacy against Candida Albicans 
compared to free drug.44 In a separate publication, the same author has recently 
developed AmB-loaded nanoparticles using chitosan (CH) and dextran sulfate (DS). 
This system was expected to be less toxic and more biocompatible compared to the 
first system which contained PEI. AmB-CH NPs showed reduced renal toxicity in 
vivo compared to Fungisome®.45 
Complexation of negatively charged DNA and RNA with various cationic 
polymers has been utilized as a means to deliver nucleic acids to treat genetic 
diseases, and infectious diseases as well as cancers. Electrostatic binding of DNA has 
some advantages over other techniques. The method is simple, uses mild preparation 
conditions, and requires no purification, whereas polymeric nanoparticles and lipid/ 
liposome formulations may involve multiple preparation and purification procedures. 
Complexation with polycations commonly prevents DNA and RNA degradation by 
nucleases. Polycations can form small and stable nanoparticles with DNA and RNA. 
Additionally, they may promote cellular uptake, endosomal escape and nuclear entry.  
Among synthetic polycations, the use of PEI is common. It can have 
transfection efficiency comparable to viral vectors.46 Theoretically, branched PEI has 
primary, secondary and tertiary amines in a 1:2:1 ratio. Due to a large number of 
amines, PEI exhibits high buffer capacity. This feature leads to a proposed proton-
sponge character which leads to osmotic swelling and endosomal membrane rupture, 
ultimately resulting in high transfection efficiency. Although PEI is efficacious, high 
toxicity is still a major concern. Various chemical modifications have been pursued to 
make PEI translatable. Partial acetylation, cleavable linkers, imidazole conjugation, 
hyaluronic acid (HA) conjugation, chitosan conjugation, and PEGylation have all 
been employed to reduce toxicity, modify biodistribution and enhance the transfection 
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efficiency of PEI.47-56 Some PEI-mediated vectors have been evaluated in clinical 
trials including jetPEI, PEG-PEI-Cholesterol and PEI-mannose and dextrose.57  
Alternatively, natural cationic polymers such as chitosan, 
poly(glycoamidoamine), schizophyllan, and dextran derivatives, can be used to 
deliver nucleic acids to avoid the relatively high toxicity of many synthetic cationic 
polymers. Several modifications were made to increase transfection levels of these 
polymers. For example, terminal amines of chitosan were N-quarternized to increase 
charge density which resulted in high transfection efficiency, albeit with higher 
cytotoxicity.58 In a later study, the same group was able to reduce this higher 
cytotoxicity by conjugation of trimethyl chitosan with PEG.59 Other examples to 
improve transfection efficiency and stability of chitosan include crosslinking with 
disulfide linkages, introducing imidazole groups, and conjugation with hydrophobic 
moieties such as deoxycholic acid, stearic acid, and alkyl chains.62-67  
Another efficient and biodegradable construct that can be used to complex 
nucleic acids involves the use of cell penetration peptides (CPPs). CPPs are short 
peptides (<30 amino acids) that usually contain basic amino acids and are protonated 
at physiological pH. Certain CPPs have been reported to cross cell membranes within 
seconds or minutes at micromolar concentrations. Therefore, CPPs are interesting 
carriers that may be used to transport electrostatically or covalently bound cargo 
across the cell membrane.  
CPPs can be classified into three groups; primary, secondary, and non-
amphipathic CCPs.60 Primary amphipathic CCPs contain both hydrophobic and 
cationic regions (> 20 amino acids). Examples of primary amphipathic CCPs are SP-
NLS, MPG, transportan, TP10, pep-1, and P (α)/(β). Secondary amphipathic CCPs, 
such as, penetratin, KLAL and RL16, are shorter and only present their amphipathic 
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properties after binding with lipids or glycosaminoglycans (GAGs). Non-amphipathic 
CCPs, for example, TAT and R9, are short and contain only cationic amino acids.  
To date, internalization mechanisms of CPPs remain elusive. It was suggested 
that a single CPP may use multiple modes to enter cells depending on experimental 
conditions. CPP cellular entry modes can be categorized into two groups: energy-
independent direct translocation and energy-dependent endocytosis. Historically, the 
penetration mechanism has been reported to be an energy- and receptor-independent 
process.61-62 Additionally, an inverted micelle mechanism has been proposed.62  
However, with the rapid development of molecular techniques, a number of recent 
reports have indicated that endocytotic mechanisms including macropinocytosis, 
clathrin-coated pits, and lipid rafts all occurred.71-76  It appears that pathways may 
vary with peptide properties (e.g. molecule length and charge delocalization), peptide 
concentration, cell types, cargo size and charge, and physiological conditions.63-66 
Descriptions of these phenomena have received less attention than their potential 
applications in drug and gene delivery.  
MPG (acetyl-GALFLGFLGAAGSTMGAWSQPKKKRKVcysteamide), a 
primary amphipathic CCP, contains a hydrophobic N-terminal region and a 
hydrophilic nuclear localizing signal (NLS) region. MPG has been used to complex 
with and deliver plasmid DNA and siRNA to a number of adherent and suspension 
cells. MPG was shown to improve DNA nuclear entry in primary cell lines and non-
dividing cells.67-68  Interestingly, MPGNLS, a mutant having a single mutation in the 
NLS region, was shown to deliver fluorescently labeled siRNA specifically to the 
cytoplasm and resulted in greater biological response, whereas MPG-transfected 
siRNA migrated rapidly to the nucleus.68 Thus, modifying the NLS of MPG allowed 
delivery of siRNA to the desired compartment, the cytoplasm. MPG has also been 
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used to deliver siRNA into mouse blastocytes and the transfected blastocytes were 
reimplanted in mice.67,69 
In addition to direct complexation, encapsulation or adsorption of nucleic 
acids in PEC formulations offers an alternative delivery method. Tiyaboonchai et al. 
have encapsulated DNA into PEI-DS particles (>95% entrapment efficiency). DNA 
remained in a supercoiled-B form after incorporation in the complexes. PEI-DS/DNA 
particles showed higher transfection efficiency compared to PEI/DNA complexes and  
dextran sulfate seemingly reduced the cytotoxicity of PEI.70 In another study, Hong et 
al. have adsorbed smad3 antisense oligonucleotides onto chitosan/ alginate 
complexes. A smad3-PEC lyophilized disk was administered topically to mice. The 
results suggested that the lyophilized disk healed wounds faster than other 
formulations.71 
1.3.2 Protein stabilization, immobilization and controlled release 
Polyelectrolyte-protein binding can happen in both cognate and non-cognate 
systems. Polyelectrolytes such as GAGs can interact with their cognate proteins to 
carry out physiological functions. There has also been increasing interest in using 
non-cognate polyelectrolytes to improve protein efficacy and stability or to extend the 
circulation half-life of therapeutic proteins. Like nucleic acids, proteins are often 
fragile. Polyelectrolyte binding offers a simple approach to stabilize, immobilize and 
control the release of therapeutic proteins. Unlike polymerization and/or conjugation 
reactions, electrostatic binding between polyelectrolytes and proteins may be done 
under mild conditions that preserve protein conformation and biological activity. 
Polyelectrolytes and proteins can bind via a number of non-covalent forces, for 
example, hydrogen bonding, salt bridges and ion pairs, and/or hydrophobic 
interactions.  
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α-Amylase, a major enzyme used in digestive enzyme supplements, has a 
relatively short shelf-life (up to 1 year when refrigerated). Sankalia et al. encapsulated 
α-amylase in chitosan-alginate PECs with 90% entrapment efficiency. The PECs were 
filled into capsules which then underwent stability testing according to the 
International Conference on Harmonization (ICH) guidelines. The stability data 
suggested that α-amylase chitosan-alginate PEC had extended the shelf-life to 3.68 
years.72 
In addition to encapsulating a small molecule drug and a nucleic acid in PEI-
DS PECs, Tiyaboonchai et al. also encapsulated insulin as a model protein drug in 
PEI-DS PECs (80-90% entrapment efficiency). The complexes had a rapid release 
profile, no insulin degradation product was detected during in vitro tests, and no 
significant conformational change was observed for insulin. Additionally, the insulin 
complexes showed an extended hypoglycemic effect in streptozotocin-induced 
diabetic rats.73 
Growth factors are secreted by a variety of cells and they regulate cellular 
activities such as migration, differentiation, and proliferation. Secreted growth factors 
bind to specific receptors and the binding subsequently initiates signal transduction 
pathways such as tissue regenerative processes. Growth factors generally have a short 
circulation half-life and undergo rapid degradation in vivo which makes it difficult to 
maintain local therapeutic concentrations.74-75 In addition, repeated administration can 
lead to negative side effects. As a result, there have been efforts to develop delivery 
systems for growth factors including lipid- and polymer-based systems including 
liposomes, solid lipid particles, lipid nanocapsules, dendrimers, polymeric 
nanoparticles, and micelles. Here, we will focus only on polyelectrolyte-based 
systems.  
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Heparin, heparin sulfates, and heparan and chondroitin sulfate proteoglycans 
are known to protect heparin binding growth factors (HBGFs) from proteolytic 
degradation and potentiate their in vitro biological effects.76-78 Interestingly, the 
binding appears to be non-specific via electrostatic interactions although with high 
affinity.79 As a result, heparin-like materials and/or polyanions have been utilized to 
promote activity or to stabilize HBGFs.79-82 
Vascular endothelial growth factor (VEGF) is a potent angiogenic cytokine 
that requires localized and sustained delivery to generate blood vessels. VEGF also 
has a short circulation half-life. Therefore, developing a sustained released 
formulation is of interest. VEGF has a heparin biding domain that can bind 
polyanions. Huang et al. complexed VEGF bound to dextran sulfate (DS) with the 
polycations, polyethylenimine, chitosan, or poly(L-lysine). The complexes had good 
encapsulation efficiencies (50-85%), extended VEGF release (up to 10 days), and the 
released VEGF remained active at day 10 of the release study.83 
 Fibroblast growth factor-10 (FGF-10), also known as keratinocyte growth 
factor-2 (KGF-2), is involved in angiogenesis, wound healing and embryonic 
development. KGF-2 has been a candidate for treatment of chemotherapy- or 
radiotherapy-induced mucositis, ulcerative colitis, and cutaneous wounds.84  Derrick 
et al. examined the effect of polyanions on the structure and stability of KFG-2 and 
found that polyanions such as heparin, sucrose octasulfate (SOS) and inositol 
hexaphosphate (IHP) stabilized KGF-2 by increasing the unfolding temperature by 9-
15oC.79 In a separate study, Huang et al. bound KGF-2 to DS and then complexed 
bound KGF-2 with polyethylenimine, chitosan, or poly(L-lysine). The unfolding 
temperature of bound KGF-2/DS was increased ~10oC. The KGF-2 bound to DS was 
packaged in PECs (entrapment efficiency 70-80%). The complexes had a sustained 
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release profile of KGF-2 up to 10 days. The mitogenic activity of the complexes on 
vascular endothelial cells was significantly enhanced.81 
In an attempt to reduce the initial burst release of human growth hormone 
(hGH) from a thermosensitive poly(organophosphazene) hydrogel, hGH (pI = 5.27), 
was complexed with polycations (poly-L-arginine or poly-L-lysine). Then, the bound 
hGH and organophosphazene polymer were heated to 37oC to convert the polymer 
solution into a hydrogel. The hGH complexed to poly-L-arginine better than poly-L-
lysine. All PECs loaded into the hydrogel showed slow release profiles compared to 
the release of hGH alone. A single subcutaneous injection of the hydrogel in Spraque-
Dawley rats showed a sustained release profile of hGH up to 5 days.85 
Polyelectrolyte multilayers: Layer-by-layer (LbL) deposition is an alternative 
method of using polyelectrolytes for controlled release. This technique has been 
widely used in tissue engineering and implantable materials. But, in this short section, 
only drug delivery applications are briefly reviewed. Polyelectrolyte multilayers 
(PEMs) are formed by alternately depositing oppositely charged polyelectrolytes onto 
surfaces of materials. The driving forces behind polyelectrolyte deposition are very 
similar to the forces involved in the formation of PECs. These forces include 
electrostatic and non-electrostatic interactions including short-range interactions such 
as hydrophobicity, hydrogen bonds, Van der Waals forces, charge transfer halogen 
interactions, and covalent bonds formed by ‘click’ chemistry.86 In addition, entropy 
gained due to the release of counterions is another force involved in multilayer 
formation.  
Various methods have been used to form PEM films such as dip coating, spin 
coating and spraying. The most common method is dip coating since it is both 
efficient and economical. The spraying method was found to be effective under 
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conditions where dipping could not produce homogeneous films. Rinsing could be 
skipped in the spraying method to accelerate the process. PEM formation exhibits two 
growth patterns; a linear and an exponential one. The exponential pattern occurs when 
one of the polyelectrolytes can diffuse in and out of the film during the deposition and 
rinsing steps.87 The chemical composition, thickness and mechanical properties of 
PEMs are important to the biological response of PEMs and these parameters can be 
controlled by changing processing conditions such as the ionic strength and pH of the 
polymer solutions.88-89 Various drugs including biomolecules such as polypeptides, 
polysaccharides, DNA, proteins, viruses and cells have been incorporated into PEM 
films. These therapeutics can be incorporated into PEMs by addition during PEM 
formation, adsorption or diffusion into the films after formation or by covalently 
binding to the constituent polymer before or after PEM formation.33 
PEM microcapsules have been used as a carrier and an adjuvant to deliver 
antigen (OVA) to the lungs. OVA was mixed with CaCl2 and NaCO3 to form OVA-
loaded CaCO3 microcapsule cores. Dextran sulfate/ poly-L-arginine PEMs were then 
alternately adsorbed onto CaCO3 particles. The capsule cores were washed away 
leaving OVA-filled PEM microcapsules. OVA-loaded microcapsules, soluble 
OVA/microcapsule mixture, soluble OVA in phosphate buffered saline (PBS) or PBS 
alone were administered to C57BL/6 mice by intratracheal instillation. FITC-dextran-
loaded microcapsules were used to track the uptake and degradation of PEM 
microcapsules. The microcapsules were taken up efficiently by pulmonary antigen 
presenting cells (APCs) and degraded completely 2 weeks after instillation. Moreover, 
OVA PEM microcapsules enhanced APC activation thus demonstrating adjuvant 
properties. Immunization with encapsulated OVA clearly stimulated a much stronger 
local Th17 response than the soluble OVA microcapsule mixture.90 In a separate 
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study, the same dextran sulfate/ poly-L-arginine PEM constructs were formulated 
with p24 antigen from human immunodeficiency virus type 1 (HIV-1) and/ or the 
Toll-like receptor ligand 3 (TLR3) ligand poly I:C, a maturation factor. The in vitro 
and in vivo data suggested that both antigen and DC maturation signals can be 
delivered as a complex with PEM capsules to stimulate a virus-specific immune 
response.91 
1.3.3 Responsive drug delivery systems 
 Responsive drug delivery systems can be categorized into two major types; 
externally regulated or open-loop systems and self-regulated or closed-loop systems. 
The externally regulated system uses external triggers such as ultrasonic, magnetic, 
electric, photonic or chemical agents to control delivery of therapeutics from the 
system. Meanwhile, self-regulated systems control and adjust the system output 
according to external variables and the release rate is controlled by a feedback 
reaction. Chen et al. has developed glucose-sensitive LbL multilayer films for self-
regulated release of insulin. The LbL multilayer film consisted of positively charged 
poly[2-(dimethylamino)ethyl methacrylate] (PDMAEMA] star polymer and 
negatively charged insulin and glucose oxidase (GOD). Star PDMAEMA bearing 
tertiary amine groups was protonated and fully extended at low pH. Under high 
glucose conditions, GOD converts glucose into gluconic acid which changes the pH 
within the film. Low pH will induce star PDMAEMA to rearrange the film 
morphology resulting in an “open” status of the film to release insulin. In vitro release 
studies showed that the film released insulin differently, depending on glucose 
concentration. In vivo data in streptozotin (STZ)-induced diabetic rats showed that the 
insulin-loaded multilayer film effectively reduced blood glucose levels.92 
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 The studies reviewed in this section demonstrated various biomedical 
applications of polyelectrolytes. Therapeutics ranging from small molecule drugs to 
macromolecules such as proteins and DNA have been delivered using a variety of 
polyelectrolyte constructs including polyelectrolyte complexes and multilayers. In 
addition to the ease of production and mild preparation conditions, polyelectrolyte-
based DDSs often offer attractive benefits such as improved drug stability during 
formulation and storage, modulation of pharmacokinetics, controlled release, and 
reduction of toxicity and side effects. More well defined and precise polyelectrolyte-
based DDSs are under development to enhance performance and ultimately maximize 
patient benefits. 
 
1.4 Thesis goal, outline and specific aims 
The overall goal of this work was to develop improved polyelectrolyte-based 
DDSs for gene and protein delivery. Macromolecular therapeutics have emerged as 
important drugs, but could often benefit from enhanced delivery. Therefore, three 
different projects have been devised to investigate potential use of polyelectrolyte-
based DDSs for gene and protein delivery. For the first project, the goal was to 
investigate the effect and relationship of surface charge and degradability of synthetic 
polymeric nanoparticles on transfection efficiency. Building upon this previous work, 
the synthetic polycation was replaced with a small cell penetration peptide (TAT 
peptide) which has very low cytotoxicity and could be optimized to have high 
transfection efficiency. In addition, LABL peptide targeting intercellular cell-adhesion 
molecule-1 (ICAM-1) was conjugated to the TAT peptide to explore targeted 
transfection as part of the second project. The third project involved development of 
anionic block copolymers that could be used to stabilize and PEGylate proteins 
bearing a heparin binding groove such as growth factors. 
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1.4.1 The effect and relationship of surface charge and degradability of polyvinyl 
amine (PVAm) nanogel on transfection efficiency 
The data presented in Chapter 2 systematically investigates the relationship of 
surface charge and degradability to transfection efficiency. Synthetic polymeric 
particles were chosen since degradability and surface charge could be precisely 
controlled. Crosslinked poly(N-vinylformamide) (PNVF) nanogels with different 
degradability were synthesized using free-radical chain polymerization. The nanogels 
were hydrolyzed to produce different degrees of polyvinyl amine (PVAm) content. 
The cytotoxicity of PVAm nanogels and the transfection efficiency of PVAm/DNA 
complexes were evaluated in human alveolar basal epithelial cells (A549). 
1.4.2 Calcium-crosslinked LABL-TAT complexes effectively target gene delivery to 
ICAM-1 expressing cells 
 Chapter 3 details the development of a new transfection agent targeted to 
ICAM-1 on cells. The upregulation of ICAM-1 is associated with diverse diseases. 
Thus, elevated ICAM-1 has been used as a target for various drugs and gene delivery. 
Synthetic versions of polycations such as PVAm (Chapter 2) were replaced with the 
CPP TAT, which was observed to yield high transfection after complexing with DNA 
and condensing with calcium. TAT, TAT-PEG, and TAT-PEG-LABL block peptides 
were synthesized. The cytotoxicity and the transfection efficiency of DNA complexed 
with these block peptides were evaluated in A549 cells overexpressing ICAM-1. The 
specificity of the targeted TAT-PEG-LABL blockpeptide was also examined. 
1.4.3 Non-covalent PEGylation by polyanion complexation as a novel means to 
stabilize Keratinocyte Growth Factor-2 (KGF-2) 
 In this chapter (4), we presented a new approach to stabilize a model HBGF, 
KGF-2, through ionic interactions with PEGylated polyanions. Repifermin is a 
truncated form of recombinant KGF-2 and was used for the treatment of 
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chemotherapy- or radiotherapy-induce mucositis, ulcerative colitis and cutaneous 
wound healing. However, Repifermin encounters several difficulties such as poor in 
vitro stability (Tm ~37
oC) and a relatively short half-life in vivo. Thus, a simple non-
covalent PEGylation using ionic interaction between readily PEGylated polyanions 
(dextran sulfate and pentosan polysulfate) and KGF-2 was investigated. The potential 
use of these PEGylated polyanions was examined through spectroscopic, calorimetric 
and light scattering techniques. 
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2.1 Introduction 
 Gene therapy represents a promising method to prevent, treat, or cure diseases. 
A major challenge of gene delivery is the balance between safety and efficiency. 
Viruses are highly efficient vectors, but often exhibit immunogenicity and 
mutagenicity. In addition, they can be difficult and expensive to produce. Non-viral 
vectors including cationic lipids and polymers have received attention due to their 
simplicity of production and gene-carrying capacity; however, they often have limited 
transfection efficiency and can exhibit significant toxicity.1 
Over the past two decades, many types of cationic polymers have been 
developed and studied as an alternative to viral vectors due to their versatility of 
physicochemical properties and easy manipulation. Charge is a key parameter of the 
polymer for DNA binding, interaction with the cell surface, endolysosomal escape, 
and subcellular localization. The nature of the polymer charge can enhance the 
transfection efficiency2-4, but may also result in undesirable cytotoxicity.  
Cytotoxicity of polymeric vectors depends upon material composition, 
exposure time, and dose.5 Besides charge density, cytotoxicity also depends on 
molecular weight and degradability of vectors.5-6 Low molecular weight 
polyethylenimine (PEI) and polylysine exhibited low toxicity in previous studies.7-9 
As a result, many groups have used low molecular weight PEI to try to avoid 
toxicity.10-12 Highly cationic vectors cause cytotoxicity by destabilizing the plasma 
membrane, interacting with cellular components, and inhibiting normal cellular 
processes, which can induce necrosis and/or apoptosis.5,13-14 Many strategies have 
been employed to reduce undesirable toxicity of polymers containing high cation 
density such as using hydrophilic, tertiary amine-based polymers15, reducing the 
number of primary amines by acetylation16, or conjugating with cyclodextrins.17 
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Degradability is also an intriguing property which may be incorporated into polymers. 
It is known that some degradable carriers can release free DNA into the cytosol 
rapidly and some have been shown to exhibit low cytotoxicity.6 Several groups have 
used biodegradable polymers such as chitosan18-20 and poly(lactic-co-glycolic acid) 
(PLGA)21 as gene carriers. A number of pH-responsive linkers such as imine22, 
diacrylate23, ketal24-25 or disulfide26 linkers have also been explored to achieve 
degradability of synthetic vectors. 
The balance between transfection efficiency and toxicity is crucial. For 
example, fully deacetylated PEI exhibiting only moderate in vitro transfection 
efficiency and low cytotoxicity have shown improved performance in vivo when 
compared to unmodified PEI.27 Many structure-bioactivity studies have been 
conducted to find suitable gene carriers. Previous findings have revealed the structural 
impact of vectors on transfection efficiency and cytotoxicity. For example, the 
proximity of amine units in polymer chains can enhance both gene expression and 
cytotoxicity.28 In contrast, liposome:DNA weight ratios had a greater impact on 
transfection efficiency than lipoplex structures.29 In another study, polylysine-graft-
imidazoleacetic acid conjugates bearing high imidazole content exhibited high gene 
expression.30 Recent studies show that amino alcohol polymers possess appreciable in 
vitro gene expression among other poly(-amino ester)s, and terminal functionality 
had great effect on in vivo transfection efficiency.31-32 Further structure-function 
studies should be performed systematically in order to better define efficient, non-
toxic and in vivo stable vectors. 
 Hydrogels have been wildly used as delivery vehicles for vaccines, proteins, 
peptides and nucleic acids due to their hydrophilic nature and biocompatibility.33-35 
Here, hydrophilic polyvinylamine (PVAm) nanogels were synthesized with controlled 
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amounts of primary amines. This system provides a means to assess cytotoxicity and 
transfection efficiency as a function of particle charge. PVAm nanogels were derived 
from Poly(N-vinylformamide) PNVF nanogels which were previously reported as 
protein carriers.36 The effect of particle degradability on transfection efficiency was 
also assessed. PVAm nanogels were crosslinked using a non-degradable crosslinker 
or an acid-labile crosslinker which contains a central ketal subject to rapid 
degradation in acidic compartments, such as in lysosomes.25,37 We anticipated that 
PVAm nanogels with different charge densities and/or degradability would provide 
different transfection efficiencies. The findings from this well-controlled polymer 
system will add to literature defining relationships between transfection efficiency and 
structure, which shall aid in the future development of gene carriers. 
2.2 Materials and methods 
2.2.1  Materials  
N-vinylformamide (NVF; Aldrich) 2, 2’-Azobis(2,4-dimethylpentanitrile 
(Vazo-52, DuPont). Tween-80,   Span-80, and 25 kDa branched PEI were purchased 
from Aldrich. All other materials were used as received. 2-(N-vinylformamido) ethyl 
ether (NVEE) and 2-Bis[2, 2’-di(N-vinylformamido)ethoxy]propane (BDEP) were 
synthesized according to the procedure previously reported.38-39 
2.2.2 Synthesis of polyvinylamine nanogel  
Polyvinylamine nanogels with controlled charge densities, derived from 
polyvinylformamide, were synthesized using inverse emulsion polymerization. 
Briefly, in the aqueous phase, vinylformamide (350 mg) was mixed with 16 mg of the 
low temperature free radical initiator, VAZO-52. Then 50 mg of crosslinker, NVEE 
or BDEP, was added and mixed. Water 165 L (or 160 L of 10 mM phosphate 
buffer pH 8.0, when BDEP is used) was added and mixed. The water phase then was 
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mixed with 100 mL of hexane, containing VAZO-52 (30 mg), Tween-80 (3.0 g) and 
Span-80 (4.1 g). The mixture was homogenized to form an inverse emulsion and 
purged with nitrogen gas. The polymerization reaction was carried out under nitrogen 
atmosphere at 50 oC for 24 h. PNVF nanogels were purified by centrifugation at 
15,000 rpm for 45 min, redispersed in water or 10 mM phosphate buffer (pH 8.0), and 
dialyzed (Spectrapor; MWCO 10,000 Da, Spectrum Laboratories Inc., CA). PNVF 
nanogels were converted to PVAm nanogels by hydrolysis using 0.1 or 0.5 N NaOH 
at 80 oC for various times as indicated in the results. PVAm nanogels were dialyzed to 
remove NaOH (Spectrapor; MWCO 2,000 Da, Spectrum Laboratories Inc., CA) and 
lyophilized (Labconco Corp., MO). Non-degradable and acid-labile PVAm nanogels 
were redispersed in water or 10 mM phosphate buffer (pH 8.0), respectively, to a final 
concentration of ~1 mg/mL. Nanogel size and zeta potential analysis was performed 
by dynamic light scattering (ZetaPALS; Brookhaven Instruments Corp., NY). To 
track the conversion of formamide side groups to amines, aliquots of non-degradable 
and acid-labile nanogels were collected at preselected time points, purified by size 
exclusion chromatography (Sephadex G-25, Chemsavers Inc., VA) and lyophilized. 
Dried nanogels were dissolved in D2O (10 mg/mL), and 
1H-NMR spectra were 
acquired (Avance 400 MHz with an H/C/P/N QNP gradient probe, probe temperature 
25 oC, 64 scans). 
2.2.3 Cell culture and plasmid DNA preparation  
Human alveolar basal epithelial cells (A549) were purchased from the 
American Type Culture Collection (ATCC) and maintained according to ATCC 
protocols, at 37 oC and 5% CO2. The 5-kilobase pair expression vector pGL3 
(Promega Corp., WI), containing the luciferase gene driven by the SV40 promoter 
and enhancer, was used. Plasmids were grown in Escherichia coli cell in Lubris 
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Bertani (LB) agar broth supplemented with 60 g/mL ampicillin and purified using 
QIAGEN plasmid Giga Kits (Valencia, CA) according to the manufacturer’s 
instructions. The DNA concentration was determined by measuring UV absorbance at 
260 nm (Agilent 8453/Agilent 89090A, Agilent Technologies Inc., CA). The DNA 
purity was determined by measuring absorbance (A). DNA with an A260/A280 ratio of 
1.8 or greater was used. 
2.2.4 Formation of polyvinylamine /DNA complexes  
DNA-nanogel complexes were prepared by adding 10 L DNA solution (0.1 
g/L) into 15 L of nanogel suspension, and mixing intensively by repeated 
pipetting and vortexing. Next, 15 L of water was added, mixed, and incubated at 
room temperature for 30 min for complex formation.  
2.2.5 Gel electrophoresis  
Complexes were prepared by adding 10 L DNA solution (0.1 g/L) into 15 
L of nanogel suspension as before, after which 4 L of Tris-acetate-EDTA (TAE) 
buffer (Promega Corp., WI) and 4 L of SYBR Green I (Invitrogen, CA) was added 
into the mixture. The mixture was incubated at room temperature for 30 min, and 7 
L of DNA loading buffer (Takara Bio Inc., Japan) was added. Then, 6 L of the 
mixture was loaded on to a 1% agarose gel (Fisher, NJ), and electrophoresed (110 V, 
30 min). A 1 kb DNA ladder (Promega Corp., WI) was used as a marker. DNA bands 
were visualized and photographed with an Alpha Imager (Alpha Innotech Corp., CA). 
2.2.6 In vitro transfection assay  
Cells were cultured in F-12 K medium (Mediatech Inc., VA) supplemented 
according to ATCC protocol and seeded in 96-well plates at 8,000 cells per well for 
24 h before transfection.  Immediately before transfection, the growth medium was 
removed, cells were washed with 100 L of phosphate buffered saline (PBS) (MP 
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Biomedicals, LLC, OH), and 100 L of complexes (500 ng plasmid per well) in 
serum free medium was added to each well. Transfection medium was replaced with 
growth medium 5 h post-transfection. Luciferase expression was measured 48 and 96 
h later using a luciferase assay (Promega Corp., WI). Luciferase activity was 
quantified in relative light units (RLUs) using a microplate reader (SpectraMax M5; 
Molecular Devices Corp., CA), and normalized by total cell protein which was 
determined using a bicinchoninic acid (BCA) assay (Thermo scientific, IL). 
Experiments were conducted in triplicate.  
2.2.7 Particle size and zeta-potential measurements  
Non-degradable and acid-labile PVAm nanogels were redispersed in water or 
10 mM phosphate buffer (pH 8.0), respectively, to a final concentration of ~1 mg/mL. 
Nanogel size and zeta potential analysis was performed by dynamic light scattering 
(ZetaPALS; Brookhaven Instruments Corp., NY).  
The size and stability of complexes was tested in serum free and growth 
medium.  Complex size was determined using a dynamic light scattering system (BT 
9000AT; Brookhaven Instruments Corp., Holtsville, NY). The mean diameter of the 
sample was obtained from the Stoke-Einstein equation using the method of 
cumulants. Complexes were then diluted with an equal volume of each medium and 
incubated at 37 oC for 4 h. The size of complexes in media over time was determined 
in the same fashion.  
2.2.8 Cell viability assay  
 Cytotoxicity was characterized using a CellTiter 96 AQueous Cell 
Proliferation assay kit (Promega Corp., WI). A549 cells were seeded in 96-well 
plates at an initial density of 8,000 cells per well in 100 μL of growth medium for 24 
h. The growth medium was replaced with fresh, serum-free medium containing 
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nanogel samples.  Cells were incubated with nanogels for 24 h, and the medium was 
replaced with complete growth medium. Then, 20 μL of MTS ([3-(4,5-
dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium]) and PMS (phenazine methosulfate) were added to each well, and the 
samples were incubated for 2 h. The absorbance was read at 490 nm, relative to blank 
wells prepared without cells, using a microplate reader (SpectraMax M5; Molecular 
Devices Corp., CA). Cell viability was expressed as the percentage of absorbance 
relative to the control (cells not exposed to the nanogels). Experiments were 
performed in triplicate. 
2.3 Results  
 Structure-transfection relationships of polycationic gene delivery vectors have 
received significant attention due to the massive demand to rationalize efficient vector 
structure.16-17,23 Charge density and degradability are well known effectors of 
transfection efficiency and cytotoxicity. PVAm nanogels represent an attractive model 
for systematically studying DNA delivery. An important feature is that PVAm 
nanogels can be hydrolyzed from PNVF nanogels to yield different charge densities. 
This allows one to examine transfection efficiency of vectors as a function of particle 
charge, which also plays a primary role in cytotoxicity.  The effect of degradability on 
transfection efficiency may also be assessed by crosslinking PVAm nanogels with 
non-degradable or acid-labile crosslinkers. Two sets of PVAm nanogels, non-
degradable and acid-labile, with various charge densities were examined to correlate 
these chemical properties to transfection efficiency and cytotoxicity.  
2.3.1 PVAm nanogel synthesis  
Non-degradable and acid-labile PNVF nanogels were synthesized using 
inverse emulsion polymerization under nitrogen atmosphere at 50 oC for 24 h. The  
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Figure 2.1. Reaction scheme for (A) non-degradable and (B) acid-labile PVAm 
nanogel synthesis. 
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size of nanogels and the hydrolysis rate of acid-labile nanogels was controlled by the 
monomer: crosslinker ratio.36,38 The monomer: crosslinker ratio 7:1 and high 
temperature (50 oC) were selected based on previous experimentation.36 These 
conditions yield small and stable nanogels and offer high yields at short reaction 
times. After purification, PNVF nanogels were converted to PVAm nanogels by 
hydrolysis of formamide side groups using NaOH at 80 oC. Nanogels were collected 
at different hydrolysis times in order to produce PVAm nanogels bearing different 
charge densities. The overall synthesis schemes for non-degradable and acid-labile 
PVAm nanogels are shown in Figure 2.1.  
The size, size distribution, and surface charge of PNVF and PVAm nanogels 
were measured by dynamic light scattering in water or 10 mM phosphate buffer pH 8 
for non-degradable and acid-labile PVAm nanogels, respectively (Table 2.1). Particle 
size and zeta potential of PVAm nanogels hydrolyzed with 0.1 and 0.5 N NaOH at 80 
oC were monitored over time (Figure 2.2). Zeta potential measurements was used to 
detected the conversion from PNVF to PVAm nanogels. The conversion rate was 
controlled by the concentration of NaOH and hydrolysis time. PVAm nanogel charge 
and size tended to increase as a function of hydrolysis time. The increase of osmotic 
pressure inside the polymer network due to counter ions coordinating with an 
increasing number of positively charged amines probably accounted for the marked 
size increase.40 Of course, the protonation of amine groups as pH decreases further 
propagates the observed size increase.41  Gradual charge increase was obtained during 
formamide hydrolysis using 0.1 N NaOH for both non-degradable and acid-labile 
PVAm. In comparison, 0.5 N NaOH, yielded a more rapid charge increase resembling 
a second order reaction, where the rate of reaction tended to strongly depend on the 
concentration of reactants. Non-degradable nanogels appeared to be less prone to size  
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Table 2.1. (A) Representative properties of PNVF and PVAm nanogels and (B) 
statistical analysis (one-way ANOVA, Tukey post test) 
 
A 
Nanogels Type 
Hydrolysis 
condition 
Effective 
diameter 
(nm±SD)* 
Polydispersity 
Zeta potential 
(mV±SD)* 
PNVF Non-degradable 
- 
 
129 ± 2.7 0.09 -11 ± 1.7 
PVAm a Non-degradable 
20 min, 80 oC, 
0.5 M NaOH 
158 ± 4.3 0.17 +8.2 ± 1.7 
PVAm b Non-degradable 
3 h, 80 oC, 
0.5 M NaOH 
116 ± 6.9 0.01 +18 ± 3.7 
PNVF Acid-labile 
- 
 
177 ± 11 0.23 -0.45 ± 2.8 
PVAm c Acid-labile 
1 h, 80 oC, 
0.1 M NaOH 
308 ± 40 0.32 +3.5 ± 0.8 
PVAm d Acid-labile 
6 h, 80 oC, 
0.1 M NaOH 
260 ± 48 0.43 +10 ± 0.4 
    
SD = Standard deviation       
 
B                                         
Effective diameter  Zeta potential  
One-way analysis of variance P<0.0001 One-way analysis of variance P<0.0001 
Tukey's Multiple Comparison Test Tukey's Multiple Comparison Test 
PNVF non-degradable vs 
PVAm c 
P < 0.001 PNVF non-degradable vs 
PVAm a 
P < 0.001 
PNVF non-degradable vs 
PVAm d 
P < 0.001 PNVF non-degradable vs 
PVAm b 
P < 0.001 
PVAm a vs PVAm c P < 0.001 PNVF non-degradable vs 
PNVF acid-labile 
P < 0.001 
PVAm a vs PVAm d P < 0.01 PNVF non-degradable vs 
PVAm c 
P < 0.001 
PVAm b vs PVAm c P < 0.001 PNVF non-degradable vs 
PVAm d 
P < 0.001 
PVAm b vs PVAm d P < 0.001 PVAm a vs PVAm b P < 0.01 
PNVF acid-labile vs PVAm c P < 0.001 PVAm a vs PNVF acid-labile P < 0.01 
PNVF acid-labile vs PVAm d P < 0.05 PVAm b vs PNVF acid-labile P < 0.001 
  PVAm b vs PVAm c P < 0.001 
  PVAm b vs PVAm d P < 0.01 
  PNVF acid-labile vs PVAm d P < 0.001 
  PVAm c vs PVAm d P < 0.05 
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Figure 2.2. Conversion rate of non-degradable PVAm nanogels with (A) 0.1 N NaOH 
(B) 0.5 N NaOH and degradable PVAm nanogels with (C) 0.1 N NaOH (D) 0.5 N 
NaOH at 80 oC over time. 
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change than acid-labile nanogels. The larger observed size increase may be due to 
some cleavage of the acid-labile crosslinker during the purification.36 As previously 
reported, the half-lives of acid-labile nanogels were 10 and 90 min and ~57 h in 
solution at pH 4.7, 5.8 and 7.4, respectively. Even though the pH of the dialysis 
medium was controlled (pH~8) in the purification step, acid-labile crosslinkers still 
hydrolyzed slowly which might have led to the larger observed size of degradable 
nanoparitcles. The conversion of formamides to amines was confirmed by 1H-NMR 
for both non-degradable and acid-labile PVAm nanogels (Figure 2.3). The decrease in 
intensity of the formamide chemical shift (-CHO, ~8 ppm) was observed in both non-
degradable and acid-labile nanogel formulations.  
2.3.2 Complex formation  
The electrostatic interaction between DNA and different nanogel formulations 
as a function of nanogel: DNA mass ratio was examined by gel electrophoresis. In 
general, both non-degradable and acid-labile PVAm with low and high surface charge 
formed complexes efficiently with plasmid DNA at nanogel: DNA ratios greater than 
3. The higher nanogel: DNA ratios bound the DNA more completely, and, eventually, 
eliminated the electrophoretic mobility of the DNA (Figure 2.4). Non-degradable and 
acid-labile nanogels bearing the more highly charged surface showed improved DNA 
condensation compared to nanogels bearing lower charge as expected.  
Dynamic light scattering was used to determine the size of the complexes. 
PVAm complexes exhibited sizes from 180-560 nm in diameter (Figure 2.5). For 
polymer: DNA complexes (e.g. PEI: DNA), the complex sizes have been reported to 
be a function of the DNA: polymer ratio.42-43 Data for PVAm complexes suggested 
that the size was related to the original size of the nanogels, thus suggesting that the 
DNA was adsorbing to the nanogel surface and not causing significant flocculation.  
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Figure 2.3. 1H-NMR spectra of (A) non-degradable PNVF and (B) non-degradable 
PVAm nanogels after hydrolysis with 0.1 N NaOH at 80 oC for 6 h and (C) acid-labile 
PNVF and (D) acid-labile PVAm nanogels after hydrolysis with 0.5 N NaOH at 80 oC 
for 3 h.  
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Figure 2.4. Gel electrophoresis of non-degradable PVAm/DNA complexes made 
from (a) 158 nm, +8.2 mV, (b) 116 nm, +18 mV, and acid-labile PVAm/DNA 
complexes made from (c) 308 nm, +3.5 mV (d) 228 nm, +11 mV.  
 
 
 
 
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Effective diameter of non-degradable (a, b) and acid-labile (c, d) 
PVAm/DNA complexes at different polymer-to-DNA ratios (n = 3 ± SD) (* = p<0.05, 
** = p<0.01, one-way ANOVA, Tukey post test). 
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Figure 2.6. Stability of (A) non-degradable and (B) acid-labile PVAm/DNA 
complexes at different nanogel-to-DNA ratios in serum free medium and (C) non-
degradable and (D) acid-labile PVAm/DNA complexes at different nanogel-to-DNA 
ratios in growth medium over time. 
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The stability of the complexes in serum-free and growth medium was also monitored 
over time (Figure 2.6). The complexes with high nanogel: DNA ratios, bearing high 
zeta potential, exhibited an increase in particle size in growth medium. The ionic 
interaction between serum protein and excess positive charge was a likely cause of the 
observed size increase and agglomeration.44 Interestingly, PEI complexes and PVAm 
complexes with low nanogel: DNA ratios retained small sizes in growth medium for 
longer periods of time. 
2.3.4 Cytotoxicity test  
The in vitro cytotoxicity of non-degradable and acid-labile PVAm nanogels 
each exhibiting low or high charge was measured using an MTS assay. Results 
indicated that cytotoxicity increased with increasing accessible charge (Figure 2.7). 
The IC50 of PEI was extremely low (~5 g/mL). The IC50 of non-degradable PVAm 
nanogels bearing charge +8.2 and +18 mV, were ~400 and 10 g/mL, whereas acid-
labile PVAm nanogels bearing charge +3.5 and +10 mV, were ~300 and 10 g/mL, 
respectively. Acid-labile nanogels bearing lower charges (e.g. +10 mV) had almost 
the same level of cytotoxicity compared to non-degradable nanogels bearing higher 
charges (e.g. +18 mV). Charge density resulting from the number and the 
arrangement of cationic residues is a key factor for cytotoxicity.5 Non-degradable 
nanogels have a globular shape, whereas acid-labile nanogels gradually degrade to 
linear oligomers as dictated by the pH of the microenvironment over time. As 
reported previously, the half-lives of acid-labile nanogels were 10 and 90 min and ~57 
h in solution at pH 4.7, 5.8 and 7.4, respectively, and the size of oligomers after 
degradation was ~14,000 Da.36 Therefore, acid-labile nanogels were expected to be 
degraded rapidly once they were endocytosed. Upon degradation, PVAm oligomers 
are linear and have more accessible cationic charges than non-degradable  
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Figure 2.7. Cytotoxicity of PEI, non-degradable (a, b) and acid-labile (c, d) PVAm 
nanogels in A549 cells. 
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nanogels. Therefore, highly flexible cationic oligomers (degradation products) could 
interact and crosslink anionic microtubules or motor proteins and perhaps lead to the 
observed cytotoxicity.45 In addition, flexible molecules have potentially greater 
interactions with membranes than rigid molecules.46 Our results also support this 
hypothesis; globular non-degradable nanogels bearing almost the same charge (+8.2 
mV, IC50 ~400 g/mL) had lower cytotoxicity compared to acid-labile nanogels (+10 
mV, IC50 ~10 g/mL). The results suggest that accessible cationic charge density 
dictate the relative cytotoxicity of nanogels in this system.  
2.3.5 Transfection   
In vitro transfection efficiency in A549 cells was systematically studied as a 
function of the nanogel: DNA ratio. Overall, the transfection efficiencies of non-
degradable and acid-labile PVAm nanogels were moderate compared to PEI (Figure 
2.8). However, this system of nanogels with similar structure, but different charge 
densities and degradability, provided a tunable model to track the relationship 
between these properties and transfection efficiency. Most PVAm nanogels exhibited 
the highest transfection efficiency after 48 h of incubation. The nanogels bearing 
higher surface charge typically yielded higher transfection efficiencies at 48 h. This is 
presumably a result of improved electrostatic interaction with cell surfaces.47 Acid-
labile complexes made from PVAm bearing a lower surface charge exhibited higher 
transfection efficiencies on day 4 compared to all other formulations. Acid-labile 
PVAm nanogels bearing high surface charge mediated markly lower gene expression. 
The observed reduction in gene expression for highly charged particles may have 
resulted from ineffective dissociation of DNA and relatively high cytotoxicity. 
Negligible transfection efficiency was observed at day 4 for all complexes made from 
non-degradable nanogels. Other rate limiting processes such as nuclear localization or  
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Figure 2.8. Transfection efficiency of non-degradable PVAm complexes made from 
(A) PVAm, 158 nm, +8 mV (B) PVAm, 116 nm, +18 mV and acid-labile complexes 
made from (C) PVAm, 308 nm, +3.5 mV (D) PVAm, 228 nm, +11 mV at different 
nanogel-to-DNA ratios 2 and 4 day post-transfection in A549 cells. 
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transcription may also be affected by the relative ability of these complexes to release 
DNA.48-51  
Size of complexes is known to be an important parameter effecting the 
endocytic pathway. It is reported that latex beads ≤ 200 nm (e.g. 50 nm and 100 nm 
and 80% of 200 nm) are exclusively taken up by clathrin-mediated endocytosis. With 
increasing size, the caveolae-mediated pathway becomes apparent. Larger beads (500 
nm) are internalized predominantly via caveolae-mediated endocytosis, a non-
degradative pathway reported to result in productive transfection.52-54 Even though 
non-degradable nanogels were smaller than 200 nm, both non-degradable and acid-
labile nanogels were 200-500 nm in size when complexed with DNA, thus suggesting 
the use both endocytosis pathways.  
Relatively high transfection efficiencies were observed at low and high 
nanogel: DNA ratios compared to medium ratios. It may be that moderate nanogel: 
DNA ratios (e.g. 6:1 and 7.5:1) formed tight complexes, impeding the dissociation of 
DNA to permit transcription. At low polymer: DNA ratios (e.g. 3:1 and 4.5:1) it is 
probable that looser complexes were formed allowing DNA to dissociate from the 
complexes more easily. At high nanogel: DNA ratios (e.g. 10.5:1), it may be that the 
increased positive charge improved recruitment of the complexes to the negatively 
charged cell surface resulting in higher transfection efficiencies despite the tight DNA 
binding. Similar results have been reported for cationic lipid/ DNA complexes and the 
results have been explained in terms of the interactions between complexes and 
cells.29,55  
Transfection efficiency of non-degradable complexes seemed to be directly 
related to the toxicity of nanogels, especially at high nanogel: DNA ratios. Non-
degradable PVAm nanogels having higher cytotoxicity yielded higher transfection 
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efficiencies. Conversely, there was no apparent correlation between cytotoxicity and 
transfection efficiency for acid-labile complexes. Acid-labile nanogels bearing low 
charge exhibited higher transfection efficiency than acid-labile nanogels bearing high 
charge. In previous reports, particles bearing degradable bonds tended to release DNA 
rapidly regardless of the charge density.6  The ability to release DNA and overall low 
cytotoxicity were likely key factors leading to sustained gene expression levels at day 
4. 
2.4 Discussion 
Gene delivery vectors should have high transfection efficiency and low 
toxicity in order to facilitate translation into the clinic. These properties have rarely 
been found in one vector. Polymers or lipids bearing high charge have improved DNA 
packaging, enhanced cell surface interaction that facilitates uptake by endocytosis, 
and improved endolysosomal escape.6,56 All of these features lead to high gene 
expression. However, it is well known that highly charged materials often have high 
cytotoxicity, aggregate readily in bodily fluids and may induce an inflammatory 
response. For example, systemic administration of lipoplexes activates the innate 
immune system rapidly and induces proinflammatory cytokines.57  
Several approaches have been reported to produce less toxic vectors. 
Generally, lower molecular weight polymers are preferred due to their corresponding 
reduction in toxicity. Many chemical modifications have been assessed to produce 
highly efficient and safe vectors. Forrest and others acetylated primary and secondary 
amines of branched, 25 kDa PEI to secondary and tertiary amides, respectively.16 The 
43% acetylated PEI showed a 26-fold higher transfection efficiency compared to 
unmodified PEI. The decrease in the number of protonable nitrogens would be 
expected to decrease endolysosomal escape via the proton-sponge mechanism. 
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However, it was suspected that the improved performance was compensated by more 
DNA release from looser complexes and an overall reduction in cytotoxicity.  
Polymer degradability is another important factor for effective gene delivery 
vehicles. Crosslinking strategies have also been utilized for producing a number of 
degradable polymers. Taking advantage of pH differences between physiological pH 
(~7) and lysosomal pH (~4-5), pH-responsive crosslinkers have been synthesized and 
incorporated into polymer backbones yielding a variety of degradable vectors.22,24-25  
Using naturally degradable polymers offers an alternative way to reduce 
toxicity. Cationic polysaccharides are water-soluble and biodegradable. Two main 
groups that have been investigated for gene delivery are chitosan derivatives and 
cationic dextrans (e.g. dextran-spermine). These materials have generally shown good 
DNA condensing ability and relatively low cytotoxicity compared to traditional 
vectors. In one study, chitosan and trimethylated chitosan showed appreciable 
transfection in two cell lines compared to PEI.20 In addition, dextran-spermine 
polyplexes showed more mild tissue and systemic toxicity in mice in comparison to 
PEI.58  
In this study, hydrophilic PVAm nanogels bearing different cationic charge 
exhibited different gene expression levels. For non-degradable nanogels, high charge 
densities yielded higher gene expression compared to nanogels with low charge 
densities as expected. The observed gene expression may result from properties of 
these nanogels such as charge density which effects complex size and stability as well 
as cell binding. Highly charged non-degradable nanogels were able to condense DNA 
into smaller complexes compared to non-degradable nanogels with lower charge. The 
small size and complex stability under physiological conditions are important factors 
for efficient gene delivery. 59 The overall net positive surface charge also enhances 
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interaction with cellular membrane surface which promotes endocytosis. For example, 
highly cationic polymers were previously described to possess high transfection 
efficiency. 5,60-61 Nagasaki et al reported cationic derivatives of Schizophyllan, a 
natural polysaccharide, showing superior transfection efficiency with an increased 
degree of amination. 62 These materials also showed higher cytotoxicity as expected. 
Interestingly, acid-labile nanogels with low charge densities yielded extended 
gene expression while maintaining lower cytotoxicity. The primary effector of the 
observed transfection efficiencies for complexes made from low charge nanogels may 
be the small complex size. A secondary effector for sustained gene expression might 
be the low toxicity of the low charge density nanogels. Even though higher charge 
polymers had higher efficiency at the same dose, they were more toxic and had lower 
efficiency with increased dose (presumably due to increased cytotoxicity). 60 Our 
results are also in accordance with findings by Miyata et al., where poly (ethylene 
glycol)-poly(L-lysine) block copolymer with reduced charge density produced by 
thiolation was found to have high transfection efficiency compared to high charge 
density copolymers with the same degree of thiolation. 63 
The data reinforced the idea that degradability and cationic charge are 
important properties of gene vectors. Balancing the two features, low charge and 
degradability, can give rise to improved transfection efficiency without compromising 
cytotoxicity. Finally, the data reiterate the need to study gene expression for longer 
periods of time, as compared to the typical 1-2 day transfection and 1 day cytotoxicity 
studies that are common today. 
Gene therapy continues to hold promise to cure a number of diseases and to 
improve disease management. But, clinical applications are not yet realized since 
there are several confounding barriers. Overcoming one barrier (e.g. cytotoxicity) has 
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typically amplified another barrier (e.g. transfection efficiency). Understanding 
polymer structural effects on transfection will help us to optimize nonviral vector 
formulations. It is probable that carefully balancing transfection efficiency and 
toxicity is a key that should be further explored to develop suitable gene vectors. 
2.5 Conclusions  
PVAm nanogels having similar chemical structure and bearing discrete 
combinations of charge densities and degradability offered a means to assess 
structure-transfection relationships for this material. PNVF nanogels were synthesized 
and crosslinked with non-degradable or acid-labile crosslinkers via an inverse 
emulsion polymerization reaction. PNVF nanogels were then hydrolyzed to PVAm 
nanogels exhibiting different charge densities. The cytotoxicity of PVAm nanogels 
increased with increasing charge accessibility. Non-degradable nanogels yielded high 
initial gene expression. Interestingly, acid-labile nanogels bearing lower charge 
exhibited more sustained gene expression offering the highest cumulative gene 
expression of any nanogel formulation. These observations suggested that transfection 
efficiency may be improved by balancing charge and degradability without 
compromising cytotoxicity.  
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3.1 Introduction 
The efficient delivery of therapeutic genes to a target site is a key to success in 
gene therapy. The basic principle of gene therapy has now been established with 
human using viral vectors. Viruses are very efficient gene vectors, but safety concerns 
such as  immunogenicity of viral proteins and risk of oncogenesis still remain.1 Both 
viral and non-viral vectors are continually under development.2 Cell penetrating 
peptides (CPPs), also called protein transduction domains (PTD), have emerged as a 
valuable component of non-viral vehicles facilitating the delivery of various 
molecules such as small molecule drugs3-4, imaging agents5-6, peptides7-8, proteins9-10, 
nucleic acids11-12, and nanoparticles13-14 across biological barriers. CPPs are relatively 
short (<30 amino acids) and usually contain multiple basic amino acids. The cationic 
properties of many CPPs allows complexation with nucleic acids, which can be 
further condensed into small nanoparticles by the addition of calcium chloride.15-16 
When translating these cationic complexes to in vivo studies, shielding with 
polyethylene glycol (PEG) and adding a peptide ligand to enable cell targeting may 
improve performance. 
The HIV-1 trans-activating transcriptor (TAT) protein was among the first 
found to be capable of translocating cell membranes and gaining intracellular access. 
Specific peptide domains were identified from this protein that maintained 
translocation ability. One specific domain, TAT49-57 (RKKRRQRRR), is one of the 
most widely studied CPPs for intracellular therapeutic delivery. TAT has been 
extensively utilized to deliver a multitude of cargo in liposomes, polyplexes, solid 
lipid nanoparticles or other nanoparticle types or by direct conjugation to molecules of 
interest.17-22 TAT peptide has also been used to form electrostatic complexes with 
DNA and siRNA to facilitate intracellular delivery. Unfortunately, the transfection 
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efficiency of TAT complexes with DNA has been relatively poor, possibly due to an 
inability to form small complexes or deactivation of this CPP when bound to nucleic 
acids.23-24 It has been suggested that high molecular weight cationic polymers offer 
stable complexes, while small polymers give rise to large, unstable complexes.24 As a 
result, many groups have attempted to improve transfection efficiency by using a 
reducible TAT polymer23 or by stringing together multiple TAT copies (e.g. TAT2, 
TAT3, and TAT4).
25-26 Recent work showed that TAT/DNA complexes have 
comparable transfection efficiency to polyethylenimine (PEI) when condensed using 
calcium.15 Calcium was reported to bind both DNA phosphate groups and/or TAT 
amine groups resulting in compact complexes with optimal DNA release.15 
Translation of these complexes may require charge shielding to avoid clearance or 
targeting to promote accumulation at diseased tissue. 
Cell adhesion molecules play an essential role in cell trafficking in the 
immune system. Intercellular cell-adhesion molecule-1 (ICAM-1), a member of the 
immunoglobulin superfamily, promotes cell adhesion in immunological and 
inflammatory reactions. It is constitutively expressed on some tissues and upregulated 
by inflammatory cytokines such as interleukin-1 (IL-1), tumor necrosis factor- 
(TNF-) or interferon- (INF-).27-28 ICAM-1 can be expressed on vascular 
endothelial cells, epithelial cells, fibroblasts, tissue macrophages, and antigen 
presenting cells.29 The upregulation of ICAM-1 is associated with diverse diseases 
such as atherosclerosis, ischemia and repurfusion, asthma, arthritis, graft rejection, 
and cancer metastasis.30-31 As a result, elevated ICAM-1 has been used as a target to 
deliver enzymes, nanoparticles, contrast agents, and antisense oligoneucleotides in an 
effort to improve health of pateints.32-38  
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LABL peptide (ITDGEATDSG) is derived from the I-domain of the L-
subunit of leukocyte function associated antigen-1 (LFA-1). LABL inhibits LFA-
1/ICAM-1 interaction by binding to the D1 domain of ICAM-1 through its active 
region, ITDGEA.39 Blocking ICAM-1/LFA-1 interactions with antibodies and LABL-
antigenic peptide conjugate have been shown to modulate disease severity and 
progression of psoriasis and experimental autoimmune encephalomyelitis (EAE), a 
model for multiple sclerosis.29,40-42 In addition to receptor binding, LABL can be 
internalized by ICAM-1 suggesting an alternative mechanism to deliver therapeutics 
into cells having elevated ICAM-1 expression.43 Recent work showed that cLABL-
conjugated nanoparticles could be successfully delivered to lung carcinoma epithelial 
cells.32 
The aim of this study was to target TAT/DNA complexes as a means to 
transfect ICAM-1 expressing cells. TAT peptide was conjugated with LABL peptide 
using a polyethylene glycol (PEG) spacer. This block peptide was then complexed 
with plasmid DNA encoding luciferase. Calcium chloride was used to condense the 
complexes, thus yielding a small size with optimized DNA release.15 At optimal 
calcium concentration, the TAT-PEG-LABL was able to target DNA to ICAM-1 
expressing cells and enhance transfection in comparison to untargeted complexes (e.g. 
TAT-PEG) offering an effective gene carrier to ICAM-1 expressing cells. 
3.2 Materials and methods 
3.2.1 Materials 
Branched polyethylenimine (PEI, 25 kDa) was purchased from Aldrich. 
Peptide conjugates were synthesized in house via solid phase peptide synthesis using 
an automated Pioneer Peptide Synthesizer (PerSeptive Biosystems, Foster City, CA). 
Resins were purchased from Applied Biosystems (Foster City, CA). Fmoc-
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(CH2CH2O)12 (MW 840, 46.5 Å spacer) and Fmoc amino acids were purchased from 
Peptide International Inc (Louisville, KY) and Advanced ChemTech (Louisville, KY), 
respectively. All peptide conjugates were purified by semi-preparative HPLC on a 
C18 column, and the purity was determined by analytical HPLC with detection at a 
wavelength of 220 nm (Shimadzu scientific instruments, Columbia, MD). The mobile 
phase was 0.1 % trifluoroacetic acid, with gradient elution using acetonitrile (15-40 % 
over 45 min). The molecular weight was confirmed by electron spray mass 
spectrometry (LCT premier mass spectrometer, Water, Milford, MA). Carcinoma 
human alveolar basal epithelial cells (A549) were purchased from the American Type 
Culture Collection (ATCC) and cultured according to ATCC protocol. Plasmid DNA 
encoding firefly luciferase (pGL3, 4.8 kbp) was obtained from Promega (Madison, 
WI). Plasmids were grown in Escherichia coli cells in Lubris Bertani (LB) broth 
supplemented with 60 g/mL ampicillin and purified using QIAGEN plasmid Giga 
Kits (Valencia, CA) according to the manufacturer’s instructions. The DNA purity 
level was determined using a UV/VIS spectrometer. DNA with an A260/A280 ratio of 
1.8 or greater was used. F-12K medium was purchased from Mediatech, Inc 
(Manassas, VA). Agarose was purchased from Fisher Scientific (Fair Lawn, NJ). 
Heparin sodium was obtained from Spectrum Chemical Mfg. Corp. (Gardena, CA). 
Recombinant, human, tumor necrosis factor- (TNF-), luciferase assay kit and 
CellTiter 96® Aqueous non-radioactive cell proliferation assay (MTS) were purchased 
from Promega (Madison, WI). Bicinchoninic acid assay (BCA) was purchased from 
Thermo Fisher Scientific Inc (Rockford, IL). Monoclonal anti-human CD54 (ICAM-
1) domain D1 and monoclonal anti-human CD54 (ICAM-1) domain D1/FITC were 
purchased from Ancell (Bayport, MN). Lipofectamine 2000, 4’,6-diamidino-2-
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phenylindole, dilactate (DAPI, dilactate), TOTO-3 and SYBR green I were purchased 
from Invitrogen Molecular Probes Inc. (Carlsbad, CA). 
3.2.2 Complex formation 
 Complex formation was conducted as described earlier.15 Briefly, complexes 
were prepared by adding 10 L (0.1 g/L) of DNA to 15 L of PEI (polymer 
nitrogen to DNA phosphate (N/P) ratio of 10) or to 15 L of TAT conjugates  (at 
desired N/P ratios) followed by intensive mixing.  Fifteen microliters of DNase free 
water or known concentrations (e.g. 150 mM) of CaCl2 solution was then added to 
PEI and TAT complexes respectively, and the solution was vigorously pipetted again. 
Complexes were allowed to incubate at 4 oC for 30 min before use. 
Lipofectamine/DNA complex was prepared according to the manufacturer’s protocol.  
3.2.3 Size and morphology 
 Complexes were prepared as described earlier. Hydrodynamic diameters of 
complex solutions were determined at 20 oC by dynamic light scattering (DLS) using 
a DynaPro plate reader (Wyatt Technology, Santa Barbara, CA). Complexes were 
analyzed in Corning 384-well UV-transparent plates using 30s data acquisitions and 
auto-attenuation laser power. The mean diameter of the sample was obtained from the 
Stoke-Einstein equation using the method of cumulants. The Dynamics Software 
package version 6.12 was used to analyze the data.  
Complex size was also examined over time in serum-free F12K medium. 
Complexes were prepared and diluted with the medium in the same manner as in 
transfection study, using 1 part of complex solution: 4 parts of medium. Complex size 
was monitored at 0, 1, 2 and 4 hrs using the DLS plate reader. 
Complexes intended for transmission electron microscopy (TEM) were air-
dried on copper grids coated with carbon film. TEM images of complexes were 
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obtained using A JEOL 1200 EXII transmission electron microscope operating at an 
accelerating voltage of 80 kV. 
3.2.4 Agarose gel electrophoresis 
Complexes were prepared as described earlier. Four L of Tris-acetate-EDTA 
(TAE) buffer and 4 L of SYBR Green I were then added into the mixture. The 
mixture was incubated at room temperature for 30 min, and 7 L of DNA loading 
buffer was added. Then, 6 L of the mixture was loaded onto a 1 % agarose gel, and 
electrophoresed at 110 V for 30 min. A 1 kb DNA ladder was used as a marker. DNA 
migration bands were visualized and photographed with an Alpha Imager (Alpha 
Innotech Corp., San Leandro, CA). 
For heparin displacement studies, complexes were challenged with 0.05 to 
0.35 U heparin for 30 min at room temperature. Complex solutions were treated with 
TAE buffer and SYBR Green I, followed by the addition of DNA loading buffer and 
electrophoresis as described above. Uncomplexed and untreated DNA diluted with 
identical electrophoresis solutions were used as a control. 
3.2.5 Cytotoxicity assay 
 Cytotoxicity of TAT conjugates and PEI was determined using a CellTiter 
96 AQueous Cell Proliferation assay kit. A549 cells were seeded in 96-well plates 
(8,000 cells/well) for 24 h prior to use. The growth medium was replaced with serum-
free medium containing TAT conjugates and PEI at various concentrations and 
incubated for 24 h. After incubation, the medium containing sample was replaced 
with 100 L of serum-free medium. Then, 20 μL of solution mixture of MTS ([3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium]) and PMS (phenazine methosulfate) were added to each well, and the 
plates were then incubated at 37 oC, 5% CO2 for 2 h. The absorbance of the formazan 
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product was measured at 490 nm using a microplate reader (SpectraMax M5; 
Molecular Devices Corp., CA).  
3.2.6 Relative ICAM-1 expression on A549 cells 
Cells were incubated with TNF- (1000 U/mL) for 24 and 48 h to activate 
ICAM-1 expression on the cell surface.44 Cells were then trypsinized, centrifuged, and 
washed three times with ice-cold PBS. Cells were divided into microcentrifuge tubes 
(5x105 cells/ 50 L). AB serum was added to block non-specific binding (25 L) and 
incubated on ice for 10 min at room temperature. Cells were washed with ice-cold 
PBS and monoclonal anti-human CD54 (ICAM-1) domain D1/FITC (80 L) was 
added and incubated on ice for 45 min. Cells were washed three times with ice-cold 
PBS and fixed with 4 % paraformaldehyde. The fluorescent intensity of cells was 
measured using a FACscan flow cytometer. Data analysis was performed using Cell 
Quest software (BD). 
3.2.7 Transfection studies 
 A549 cells were seeded in 96-well plate (8,000 cells/well) for 24 h prior to 
transfection or activation of ICAM-1. Cells were incubated with TNF- (1,000 U/mL) 
for an additional 48 h for transfection studies on cells with up-regulated ICAM-1. 
Complexes were prepared as described earlier. Prior to transfection, growth medium 
was removed and cells were washed with PBS (100 L) twice. Complexes (20 L) 
were diluted with serum-free medium (80 L) and then were added to each well. 
After 5 h of transfection, transfection medium was replaced with growth medium and 
cells were incubated for another 48 h. The luciferase assay kit was used to determine 
gene expression. Cells were harvested and luciferase expression was measured 
according to the manufacturer’s protocol. Luciferase activity was quantified in 
relative light units (RLUs) using a microplate reader (SpectraMax M5; Molecular 
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Devices Corp., CA), and normalized by total cellular protein which was determined 
using a bicinchoninic acid (BCA) assay. 
 Transfection parameters such as CaCl2 concentrations (0-300 mM) and N/P 
ratios (5–30) were optimized using TAT and TAT-PEG complexes in normal A549 
cells. For targeting, studies in cells activated using TNF-α, 25 and 50% of the TAT-
PEG-LABL were selected to be incorporated into complexes (the remainder was 
TAT-PEG). Previous work demonstrated that increasing ligand density (e.g. from 
25% to 50%) increased the binding and uptake of particles targeting ICAM-1 
receptors.45 Particles with 50% targeting ligand showed the highest interaction 
compared to other formulations. Increasing ligand density (e.g. 75% and 100%) 
resulted in decreased binding and uptake of the particles.  
 The effect of ICAM-1 receptor blocking on transfection efficiencies of 
targeted complexes was also examined. Activated cells were incubated with various 
concentrations of free LABL peptide or anti-ICAM-1 mAb for 30 min. Cells were 
then washed three times with serum-free medium and incubated with 50% TAT-PEG-
LABL/DNA and TAT/DNA complexes for 5 h. Luciferase expression was measured 
as described above. 
3.2.8 Confocal microscopy of internalization 
 DNA was fluorescently labeled with the intercalating nucleic acid stain 
TOTO-3 using a molar ratio of 1 dye molecule per 300 base pairs for 30 min at room 
temperature in the dark. Then, complexes were prepared as described earlier with the 
labeled DNA. A549 cells were mounted onto glass slides and activated with TNF- . 
Cells were then incubated with complexes for 4 h. Cells were then washed three times 
with ice-cold PBS and fixed with 4 % paraformaldehyde. Nuclei were labeled with 
DAPI dilactate (300 nM, ex: 358 nm, em: 461 nm) for 5 min at 37 oC, 5 % CO2. Cells 
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were observed using an Olympus Spinning Disk Confocal Microscope and TIRF-M 
inverted fluorescence microscope using 20X or 60X objectives (DAPI, ex: 387 nm, 
em: 415-470 nm, TOTO-3, ex: 628 nm, em: 669-726 nm). Bright field transmission 
images were obtained at the same time.  
3.2.9 Statistic analysis 
 GraphPad Prism 4 software was used for statistical analysis. Statistical 
significance for differences between two data sets was determined by unpaired 
Student’s t-test (95% confidential interval). One-way ANOVA, Tukey post test was 
used to analyze the differences when more than two data sets were compared. 
3.3 Results 
3.3.1 Purification and characterization of TAT, TAT-PEG, and TAT-PEG-LABL 
 All TAT peptide conjugates were synthesized according to a standard Fmoc 
protocol. The crude peptide and conjugates were purified by semi-preparative HPLC 
on a C18 column, and the purity was determined by analytical RP-HPLC (purity >95 
%) (Figure 3.1). The expected molecular weight was confirmed by electrospray 
ionization mass spectrometry; TAT MW 1338.9 Da, TAT-PEG MW 1939.2 Da, 
TAT-PEG-LABL MW 2885.6 Da (Figure 3.2). 
3.3.2 Physicochemical characterization of complexes 
An important characteristic for efficient gene delivery using cationic polymers 
is the formation of small and stable complexes with DNA.46 The ability of TAT and 
TAT conjugates to form complexes with DNA was studied using agarose gel 
electrophoresis at N/P ratios of 0, 1, 2, 3, 4, 5, 10, 20, and 30. The immobilization of 
DNA suggested that TAT and TAT-PEG conjugates were able to form complexes 
with DNA and completely immobilize DNA starting at an N/P ratio of 1 and 2, 
respectively (Figure 3.3). Targeting ligands (TAT-PEG-LABL) were included at  
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Figure 3.1. HPLC chromatograms for TAT, TAT-PEG, and TAT-PEG-LABL 
confirmed purity > 95%. 
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Figure 3.2.  Electrospray ionization (ESI) mass spectra of (A) TAT, (B) TAT-PEG, 
and (C) TAT-PEG-LABL were in agreement with calculated masses. 
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various ratios with TAT-PEG and DNA mobility was assessed at an N/P ratio of 30. 
Targeted TAT conjugates in all formulations (e.g. 25, 50, and 75 % TAT-PEG-
LABL) were able to immobilize DNA. The data also suggested that PEGylation did 
not negatively affect the ability of TAT to complex with DNA at N/P ratios ≥2. 
The hydrodynamic diameters and morphology of the complexes were 
evaluated by DLS and TEM, respectively. TAT, TAT-PEG, 25 % TAT-PEG-LABL, 
and 50 % TAT-PEG-LABL complexes were prepared at an N/P ratio of 30 and in the 
presence of various concentrations of CaCl2. Complexes with discrete percentages of 
targeting ligands were prepared by varying the relative amounts of TAT-PEG and 
TAT-PEG-LABL (e.g. 25% or 50% TAT-PEG-LABL). The complex size in 
deionized water varied with CaCl2 concentration (Figure 3.4A). TAT and TAT-PEG 
complexes were generally smaller than 25 % and 50 % TAT-PEG-LABL complexes. 
Without CaCl2, most complexes were quite large (>400 nm) as determined by DLS. 
When adding 30 mM CaCl2, the complexes were larger than the initial size 
suggesting that a low concentration of CaCl2 may induce aggregation. Adding 150 
mM CaCl2 yielded a minimum diameter for most complexes (110, 190, 290 nm for 
TAT, TAT-PEG, and 50 % TAT-PEG-LABL complexes, respectively). The data 
suggested that the TAT peptide could not condense DNA well without calcium 
chloride and that an optimal amount of calcium chloride is essential to form compact 
particles. Comparing the size of TAT and TAT-PEG complexes suggested that 
PEGylation increased the hydrodynamic diameter as observed by others.47  
Complex size in serum-free F12K media was also determined over time. TAT, 
TAT-PEG, 25 % TAT-PEG-LABL, and 50 % TAT-PEG-LABL complexes were 
prepared as described earlier at an N/P ratio of 30 and in the presence of various  
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Figure 3.3. Gel electrophoresis of (A) TAT/DNA and (B) TAT-PEG/DNA complexes 
at different N/P ratios. (C) TAT-PEG-LABL/DNA complexes at an N/P ratio of 30 
with different amounts of TAT-PEG-LABL combined with TAT-PEG. All complexes 
at all N/P ratios limited the mobility of DNA. 
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Figure 3.4. DLS was used to determine the size of TAT/DNA, TAT-PEG/DNA, 25% 
TAT-PEG-LABL/DNA, and 50% TAT-PEG-LABL/DNA complexes at an N/P ratio 
of 30 with different concentration of CaCl2. (A) The hydrodynamic diameters of 
complexes were determined in deionized water and (B) in serum-free F12K media. 
(C) The hydrodynamic diameter of complexes (formed with 150 mM CaCl2) in F12K 
media were stable over time. For missing data points, diameter was >1 m. 
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concentrations of CaCl2. Complexes were handled similarly to transfection studies. 
Generally, most complexes in media (Figure 3.4B) were substantially smaller than in 
deionized water (Figure 3.4A). At lower or higher CaCl2 concentration (75 and 300 
mM), particle size was initially larger than at CaCl2 150 mM, but no precipitation was 
observed (Figure 3.4B). The hydrodynamic diameter was also monitored for 
complexes with 150 mM of added CaCl2 for 4 h. Complexes were small and stable 
over time (Figure 3.4C).  
The morphology of complexes was characterized using transmission electron 
microscopy (TEM). TAT, TAT-PEG, 25 % TAT-PEG-LABL, and 50 % TAT-PEG-
LABL complexes were prepared as described earlier at an N/P ratio of 30. 
Formulations without CaCl2 were compared to those including 75 mM CaCl2. TEM 
images indicated that most complexes had a globular shape and were substantially 
smaller than 300 nm (Figure 3.5), but images reflect the dry state. Agglomerates were 
occasionally visible in these samples and may account for the larger diameters 
observed by DLS or may be attributable to sample drying. This difference between 
the DLS data and TEM data could be due to small amount of flocculates observed 
from DLS experiments. The flocculates (~1 m, <5% of population) have greatly 
shifted the mean diameter, which is a major disadvantage of DLS.  
Forming complexes with polycations can protect DNA from degradation and 
often effectively condenses DNA, but DNA release is also crucial for enhancing 
transfection efficiency.48 Complex stability was evaluated by displacing DNA using 
heparin. TAT, TAT-PEG, 25 % TAT-PEG-LABL and 50 % TAT-PEG-LABL 
complexes were tested in this experiment. The complexes were formed at an N/P ratio 
of 30 using various concentrations of CaCl2 and challenged with free heparin (Figure 
3.6). TAT complexes yielded the most stable DNA complexes, whereas TAT-PEG  
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Figure 3.5. Transmission electron micrographs of (A) TAT/DNA, (B) TAT/DNA-Ca, 
(C) TAT-PEG/DNA, (D) TAT-PEG/DNA-Ca, (E) 25% TAT-PEG-LABL/DNA, (F) 
25% TAT-PEG-LABL/DNA-Ca (G) 50% TAT-PEG-LABL/DNA, and (H) 50% 
TAT-PEG-LABL/DNA-Ca complexes. Complexes were formed at an N/P ratio of 30 
without CaCl2 (left panel) or with 75 mM of CaCl2 (right panel). Scale bars are 500 
nm. 
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Figure 3.6. A heparin displacement assay for (A) TAT/DNA, (B) TAT-PEG/DNA, 
(C) 25% TAT-PEG-LABL/DNA, and (D) 50% TAT-PEG-LABL/DNA complexes 
was used to assess the effect of calcium chloride concentration (0, 30, 75, 150, 300 
mM) on complex stability. Complexes were formed at an N/P of 30 and incubated for 
30 min with increasing heparin concentrations (0.05-0.35 U). Free DNA is shown as a 
control (C) to the left.  
88 
complexes had the lowest stability. The 25 % TAT-PEG-LABL and 50 % TAT-PEG-
LABL complexes showed intermediate stability between TAT and TAT-PEG 
complexes. At all CaCl2 concentrations, TAT complexes were very stable and did not 
release DNA even at high heparin concentration (Figure 3.6A). TAT-PEG complexes 
were most stable at a CaCl2 concentration of 75 mM; however, some DNA mobility 
was observed at most all CaCl2 concentrations (Figure 3.6B). The stability of 25 % 
TAT-PEG-LABL and 50 % TAT-PEG-LABL complexes also depended on CaCl2 
concentration. Fifty percent TAT-PEG-LABL complexes started to release DNA at a 
CaCl2 concentration of 150 mM and DNA was substantially displaced by heparin at a 
CaCl2 concentration of 300 mM (Figure 3.6D).  
3.3.3 Cytotoxicity, transfection efficiency, and intracellular accumulation of 
complexes 
 Toxicity is a major issue with many non-viral vectors and a correlation 
between high toxicity and improved transfection efficiency is often reported.49 The 
cytotoxicity of TAT, TAT-PEG, and TAT-PEG-LABL in unactivated and activated 
A549 cells overexpressing ICAM-1 was evaluated and compared to PEI. After 24 hrs 
of incubation, TAT, TAT-PEG, and TAT-PEG-LABL revealed negligible 
cytotoxicity, whereas PEI showed extreme cytotoxicity with an IC50 value of ~50 and 
~10 g/mL in normal and activated cells, respectively (Figure 3.7). At high 
concentration, TAT-PEG had slightly less cytotoxicity than TAT in unactivated cells 
(Figure 3.7A).  
 Transfection efficiency was determined in A549 cells. This cell line may be 
activated by proinflammatory cytokines to overexpress ICAM-1. In order to optimize 
transfection parameters such as CaCl2 concentration and N/P ratios, transfection 
studies of TAT/DNA and TAT-PEG/DNA complexes were evaluated in unactivated  
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Figure 3.7. TAT peptide and derivatives showed low cytotoxicity in comparison to 
PEI (A) in unactivated and (B) in activated A549 cells, which overexpress ICAM-1. 
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Figure 3.8. Transfection efficiencies of TAT peptide derivative/DNA complexes in 
A549 cells. (A) TAT/DNA and TAT-PEG/DNA complexes at an N/P ratio of 30 with 
different concentrations of calcium chloride (B) TAT/DNA complexes at different 
N/P ratios (C) TAT-PEG/DNA complexes at different N/P ratios. L= Lipofectamine. 
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A549 cells (Figure 3.8). Luciferase gene expression was measured 48 hrs post-
transfection and compared to PEI and Lipofectamine 2000. Generally, TAT and TAT-
PEG complexes showed relatively low transfection efficiencies in the absence of 
CaCl2 and at low CaCl2 concentrations (e.g. 5 and 30 mM). TAT complexes showed 
the highest transfection efficiency at 150 mM added CaCl2 (Figure 3.8A). TAT-PEG 
complexes showed slightly lower and a similar trend of transfection efficiency 
compared to TAT complexes.  The data suggested that CaCl2 concentrations around 
150 mM provided optimal transfection, perhaps due to the small complex size, DNA 
protection, and/or efficient DNA release.  
Next, the transfection efficiencies of TAT and TAT-PEG complexes at 
different N/P ratios were examined at CaCl2 concentrations of 0, 30, and 75 mM. 
Using 75 mM of added CaCl2, N/P ratios between 10 and 20 yielded high transfection 
levels for TAT complexes, exceeding the performance of PEI and Lipofectamine 
2000 (Figure 3.8B).  TAT-PEG complexes showed a somewhat similar trend, 
reaching the maximum transfection level at N/P ~30 and at the highest calcium 
concentration of 75 mM (Figure 3.8C). Transfection levels of TAT-PEG complexes 
were substantially lower than TAT complexes, as expected. The reduced transfection 
level of TAT-PEG was in agreement with complex stability data since TAT-PEG was 
less effective at packaging DNA (Figure 3.6B).  
Relative ICAM-1 receptor expression levels in A549 cells after activation with 
TNF- for 24 and 48 h was quantified using FITC-labeled monoclonal anti-human 
CD54 (anti-ICAM-1) and a FACscan flow cytometer. The fluorescence intensity 
representing the relative ICAM-1 expression level showed 22-fold and 41-fold 
increases in A549 cells after 24 and 48 h of activation compared to normal cells, 
respectively (Figure 3.9).  
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Relative ICAM-1 expression level in A549 cells after activation with 
TNF- for 24 h and 48 h (* = p<0.05, t-test). 
 
 
 
 
 
 
 
 
 
 
93 
 Transfection efficiencies of TAT derivative complexes (e.g. TAT, TAT-PEG, 
25 % and 50 % TAT-PEG-LABL + TAT-PEG) in A549 cells with upregulated 
ICAM-1 at different concentrations of calcium chloride were examined. Cells were 
activated with TNF- for 48 h prior to transfection. Complexes were formed at an 
N/P ratio of 30 and luciferase gene expression was measured 48 hrs post-transfection. 
Overall, complexes formed with 150 mM of added CaCl2 showed superior 
transfection efficiency compared to complexes formed with other CaCl2 
concentrations (Figure 3.10). Data were consistent with transfection data in normal 
cells, which showed maximum transfection levels at 75 and 150 mM CaCl2 (Figure 
3.8A).  In both normal and activated cells, TAT complexes showed transfection 
efficiencies (150 mM CaCl2) that were comparable to PEI and Lipofectamine 2000.  
 As anticipated, TAT-PEG complexes showed the lowest gene expression 
level; however, transfection efficiency was regained by including targeting ligands 
(TAT-PEG-LABL) in the formulations. Including twenty five percent TAT-PEG-
LABL with TAT-PEG gave improved transfection efficiency compared to TAT-PEG, 
and 50% TAT-PEG-LABL complexes achieved the highest transfection level for 
targeted complexes (75 and 150 mM CaCl2). The observed transfection efficiency 
was consistent with complex size. According to DLS data, complex sizes at 150 mM 
CaCl2 were small (100-200 nm) and stable in the medium.  
A blocking study was performed to determine the effect of ICAM-1 receptor 
blocking on transfection efficiency of targeted complexes. TAT/DNA and 50% TAT-
PEG-LABL/DNA complexes were formed as described earlier at an N/P ratio of 30 
using 150 mM CaCl2. Activated cells were incubated with various concentrations of 
free LABL peptide or anti-ICAM-1 mAb prior to exposure to TAT complexes. The 
reduced transfection levels of targeted complexes (Figure 3.11) suggested that the  
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Figure 3.10. Transfection efficiencies of TAT peptide derivative/DNA complexes in 
activated A549 cells (overexpressing ICAM-1) at different concentrations of calcium 
chloride. Complexes were formed at an N/P ratio of 30. L= Lipofectamine (* = 
p<0.05, one-way ANOVA, Tukey post test). 
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Figure 3.11. Transfection efficiencies of TAT/DNA and 50% TAT-PEG-LABL/DNA 
complexes in activated A549 cells (overexpressing ICAM-1) after incubation with 
free LABL peptide or anti-ICAM-1 mAb prior to exposure to TAT complexes. 
Complexes were formed at an N/P ratio of 30 and 150 mM CaCl2. (* = p<0.05, ** = 
p<0.01, one-way ANOVA, Tukey post test). 
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binding of targeted complexes to ICAM-1 on activated A549 cells was hindered when 
free LABL peptide or anti-ICAM-1 mAb was added. Inhibition was dose dependent 
with higher LABL concentrations leading to lower transfection. It is worth noting that 
activated A549 cells exhibited substantially lower transfection when compared to 
normal cells.  Transfection efficiencies of PEI and Lipofectamine 2000 in activated 
cells were significantly reduced compared to normal cells. Interestingly, 25% and 
50% TAT-PEG-LABL complexes were able to maintain transfection levels in both 
normal and activated cells (Figure 3.12).  
Targeted complexes were expected to enhance binding and internalization 
compared to untargeted complexes in activated ICAM-1 expressing cells. Untargeted 
(TAT-PEG) and targeted complexes (50 % TAT-PEG-LABL) were imaged by 
confocal microscopy. DNA was fluorescently labeled using TOTO-3. Both complexes 
were formed with labeled DNA under the same conditions (CaCl2 150 mM, N/P = 30) 
and incubated with activated cells for 4 h. DNA in TAT-PEG complexes was difficult 
to detect in culture.  Conversely, DNA from 50 % TAT-PEG-LABL complexes were 
observed in the vast majority of the cells and overlayed both the cell bodies and nuclei 
(Figure 3.13).  
3.4 Discussion 
Despite its low molecular weight, TAT was confirmed as a powerful 
transfection agent when condensed with an optimal concentration of CaCl2. Targeting 
ligands are expected to improve the performance of these types of vectors when 
translated to in vivo studies. Therefore, TAT was modified with PEG and the peptide 
LABL, a well-characterized ligand for ICAM-1.  TAT, TAT-PEG, and TAT-PEG-
LABL block peptides were carefully synthesized and the structure validated.  In 
general, all forms of TAT showed minimal cytotoxicity. TAT-PEG had less  
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Figure 3.12. Transfection efficiencies of 25% and 50% TAT-PEG-LABL/DNA 
complexes in normal and activated A549 cells. Complexes were formed at an N/P 
ratio of 30 and and 150 mM CaCl2. (* = p<0.05, t-test) 
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Figure 3.13. Micrographs of (A) TAT-PEG/DNA complexes and (B) 50% TAT-
PEG-LABL/DNA complexes in A549 cells (activated with TNF-) after 4 h of 
incubation at 37 oC. Complexes were formed at an N/P ratio of 30 and a CaCl2 of 150 
mM. (1 = DAPI fluorescence (cell nuclei), 2 = TOTO-3 fluorescence (DNA), 3 = 
Merged DAPI and TOTO-3 fluorescence, 4 = Merged DAPI, TOTO-3 fluorescence, 
and bright field transmission.) 
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cytotoxicity than TAT in unactivated A549 cells. Earlier reports suggest PEGylation 
often reduces cytotoxicity of cationic polymers.50-51 The CaCl2 concentration range 
used in this study was relatively safe. The IC50 value of CaCl2 was ~210 mM for 
A549 cells.15 Final concentrations of CaCl2 used with cells in transfection studies 
ranged from 1-60 mM (corresponding to the reported starting concentrations of 5-300 
mM) which were far below this IC50 value.  
TAT and TAT-PEG were able to immobilize DNA starting form N/P ratios 1 
and 2, respectively. The data  were consistent with previous reports that indicated 
TAT can immobilize DNA at an N/P ratio as low as ~2.15,25 The data also suggested 
that PEGylation and incorporation of targeting ligand did not interfere with DNA 
complexation.  
Size and morphology of block peptide/DNA complexes were then 
characterized. Complex stability was also examined using heparin displacement. The 
data suggested that CaCl2 played a critical role on complex size and DNA release. At 
optimal CaCl2 concentration (150 mM CaCl2), complexes were small and stable in 
the medium. It is probable that calcium bridges between DNA phosphate groups 
and/or TAT amine groups helped condense complexes into compact particles.15 Ionic 
strength is known to affect the size of nanoparticle formulations, especially for 
charged particles. It was reported that adding calcium and magnesium (>30 mM) 
reduced aggregation and yielded more monodisperse plasmid-lipid nanopaticles.52  
In addition to controlling particle size, calcium concentration also affected 
DNA release. For example, 50% TAT-PEG-LABL complexes started to release DNA 
at a CaCl2 concentration of 150 mM and DNA was substantially displaced by heparin 
at a CaCl2 concentration of 300 mM (Figure 3.6D).  A previous study suggested that 
TAT complexes may be “loosened” at high calcium concentration as evidenced by 
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fluorescent DNA probes.15 Ionic strength may also contribute to the observed 
destabilization. It has been reported that, at low salt concentration (≤ 50 mM NaCl), 
polymer-DNA binding is not strongly dependent on ionic strength. High salt 
concentration, however, can alter polymer-DNA binding and may cause dissociation 
of complexes due to electrostatic shielding.53 The stability of polycation/ DNA 
complexes has been identified as a rate limiting step for intracellular release of DNA, 
which can impair transfection efficiency. Previous reports showed ‘weak’ chitosan 
polyplexes offered a faster onset of transfection and higher gene expression both in 
vitro and in vivo.54 Therefore, a fine balance between complex stability and DNA 
release is essential for efficient transfection. Tuning calcium concentration provides a 
simple formulation approach for optimizing TAT complex size and DNA release. 
Transfection efficiencies of TAT and TAT-PEG in A549 cells were enhanced 
by optimizing calcium concentration. The data suggested that small complex size, 
optimal complex stability and DNA release may contribute to the improved gene 
expression. Calcium has been shown to enhance transfection efficiency for lipid gene 
delivery systems.52,55-57 The detailed mechanism of calcium enhancement for these 
systems has not been clear and several mechanisms have been proposed.52,56-57 It was 
suggested that calcium may increase membrane association or cellular uptake of 
complexes or particles. More importantly, calcium may act as a lysosomotropic agent 
and destabilize endosomal and/or lysosomal membranes thus increasing endo-
lysosomal release. Interestingly, Fujita and others reported that calcium did not 
improve the performance of arginine-PEG-lipid-coated DNA/ protamine complexes.55 
Generally, substantially higher calcium concentrations were used to condense and 
control DNA release from modified TAT complexes reported here.  
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Several groups have used TAT peptides at high N/P ratios possibly because 
TAT peptides have also been shown to lose membrane translocation ability upon 
binding to DNA.25,58 It was reported that excess free TAT peptides enhanced 
transfection efficiency of TAT/DNA complexes by preventing complex disruption by 
proteoglycans.59 Interestingly, it was also previously reported that large amounts of 
free PEI remained in PEI/DNA mixtures. The presence of free PEI was suggested to 
improve membrane permeability, thus enhancing DNA release into the cytoplasm.60 
Adding the PEG block served as a hydrophilic arm for attaching targeting 
ligands with the goal of recovering transfection efficiency and adding specificity. 
LABL, a peptide ligand for ICAM-1 was linked to TAT-PEG using solid phase 
synthesis. The resulting TAT-PEG-LABL was confirmed using mass spectrometry 
(Fig. 3.2), and used in studies with activated A549 cells, which overexpress ICAM-1.  
TAT-PEG-LABL and TAT-PEG were mixed at different ratios resulting in a different 
percentage of targeting ligands when forming complexes with DNA. This targeted 
gene delivery system was then explored their ability to transfect A549 cells 
overexpressing ICAM-1. PEGylation significantly reduced transfection efficiency 
when compared to unmodified TAT as expected. The low transfection observed for 
TAT-PEG complexes was consistent with poor complex stability and with previous 
reports that indicated PEG-based polymers or liposomes had reduced transfection 
levels, possibly due to steric hindrance.18,53 Transfection efficiency was recovered by 
incorporating the LABL targeting ligand.  
Complexes containing 50% TAT-PEG-LABL 75 and 150 mM showed high 
transfection levels when 75 and 150 mM CaCl2 was added. The relatively low 
transfection efficiencies of 25% and 50% TAT-PEG-LABL complexes at 300 mM 
CaCl2 may be due to their large sizes (430 and ~900 nm, respectively) in the medium 
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and inadequate ability to protect DNA as suggested by heparin displacement data. It 
was previously reported that particles smaller than ~200 nm were internalized mainly 
by endocytosis, whereas particles larger than ~200 nm were taken up primarily by 
phagocytosis.61 It was also reported that when phagocytosis occurs, transfection 
efficiency can be reduced.16 The blocking data strongly supported a specific, ICAM-1 
receptor mediated interaction. 
PEI and Lipofectamine 2000 showed significantly reduced transfection levels 
in activated cells compared to normal cells. Exposure to TNF-, a pro-inflammatory 
cytokine, can alter cellular functions. Previous reports showed that TNF- decreased 
cell viability in primary and immortalized cell lines.62-63 Some studies have also 
shown that, under inflammatory conditions, cells often have decreased endocytic 
activity and different endocytic pathways may be favored.64 This is important 
evidence that certain cell types may be more difficult to transfect due to abnormal 
cellular functions under pathological conditions. 
3.5 Conclusions 
The observed transfection efficiency of targeted complexes resulted from a 
combination of optimal complex size, complex stability, DNA release, and the 
presence of targeting ligands. These characteristics are well known to effect 
internalization and DNA release, and the resulting transfection efficiency. The 
performance of targeted TAT-PEG-LABL suggested that these complexes may be a 
promising vector for targeted gene transfection to sites of inflammation in vivo. 
Although accurate targeting of TAT-PEG-LABL complexes was demonstrated here, it 
may be necessary to investigate other epithelial, endothelial, or inflammatory cell 
lines. 
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Non-covalent PEGylation by polyanion complexation as a 
novel means to stabilize Keratinocyte Growth Factor-2 
(KGF-2) 
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4.1 Introduction 
Therapeutic proteins such as antibodies, cytokines, growth factors and 
enzymes are increasingly important in the treatment of difficult to treat diseases such 
as viral infections, malignant cancers, and autoimmune disorders. The use of protein 
therapeutics has grown dramatically and is predicted to expand 15-20 % annually.1 
The development of therapeutic proteins can be impeded by several problems such as 
insufficient stability, short biological half-life, immunogenicity, and costly 
production.2  
Approaches to improve the stability and pharmacokinetic properties of 
therapeutic proteins include structural modification and covalent conjugation of 
polyethylene glycol (PEGylation). PEGylation can provide multiple benefits. Some 
proteins exhibit a short half-life because of fast renal clearance, often a result of their 
small size and hydrophilicity.2 PEGylation increases protein molecular weight, which 
can prolong plasma half-life allowing less frequent administration. Additionally, PEG 
can physically mask the protein, which can improve stability and decrease 
immunogenicity. A common consequence of PEGylation is a reduction in biological 
activity, but a significant increase in biological half-life may outweigh this 
disadvantage.3 Several PEGylated protein products have received approval including 
PEGylated asparaginase (Onspar), PEGylated adenosine deamidase (Adagen) and 
PEGylated interferon (PEG-Intron and PEG-Asys).4  
Fibroblast growth factors (FGFs) are small polypeptide growth factors sharing 
common structural characteristics. They bind to glycosaminoglycans as well as 
polyanions such as heparin. The binding of FGFs to proteoplycans such as heparan 
sulfate serves to protect FGFs from degradation and to create local reservoirs of 
growth factors.5 Proteoglycans also present FGFs to their cell surface receptors in a 
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biologically active form.6-7 The heparin-binding domains of FGFs constitute clusters 
of basic amino acid residues brought together by the secondary and tertiary structure 
of the folded polypeptide.8-10 Heparin, heparan and chondroitin sulfate proteoglycans 
are also reported to protect HBGFs from proteolytic degradation and potentiate their 
biological effects.11-13  
Fibroblast growth factor-10 (FGF-10) also known as keratinocyte growth 
factor-2 (KGF-2) is a 208 amino acid glycoprotein expressed in stromal cells.14 KGF-
2 has a sequence similar to FGF-7 (KGF-1) and both are highly mitogenic for 
keratinocytes.15 Repifermin is a truncated form of recombinant FGF-10 containing 
140 amino acids. Repifermin was reported to promote angiogenesis and accelerate 
wound healing and was a potential candidate for the treatment of mucositis, ulcerative 
colitis and cutaneous wound healing.16-19  Repifermin development has been 
impeded, however, by poor stability and a relatively short half-life in vivo.20-21 The 
protein unfolds around body temperature (~37 oC) and the unfolded protein aggregates 
rapidly.22 Thus, an improved thermal stability and an extended biological half-life are 
highly desirable. In this work, the non-covalent PEGylation of KGF-2 is explored by 
electrostatically complexing the PEGylated polyanions pentosan polysulfate (PPS) 
and dextran sulfate (DS). PPS and DS are sulfated polysaccharides (Figure 4.1). DS 
has been reported to protect many fibroblast growth factors from heat, acid, and 
proteolytic degradation at low ionic strength.23-25 PPS has been used to treat 
interstitial cystitis, transmissible spongiform encephalopathies (TSEs) and various 
forms of cancer and is currently being evaluated as an antiviral agent and anti-tumor 
agent as well.26-28 PPS is capable of stabilizing FGF-1 against heat-induced 
aggregation.29 The aim of this work is to test the ability of these PEGylated 
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Figure 4.1. Representative structures of (A) pentosan polysulfate (PPS) and (B) 
dextran sulfate (DS). 
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polyanions to increase the thermal stability of KGF-2 and provide general reagents to 
favorably alter the properties of these potential therapeutic proteins. 
4.2 Materials and methods 
4.2.1 Materials 
Repifermin, a truncated form of KFG-2, was obtained from Human Genome 
Sciences (HGS). DS sodium (MW 5 kDa), branched polyethylenimine (PEI, MW 25 
kDa), phosphate buffered saline (PBS), and 2-mercaptoethanol were purchased from 
Sigma (St. Louis, MO). PPS sodium (MW 4-6 kDa) was purchased as solution for 
injection from the Wedgewood Pharmacy (Swedesboro, NJ). Methoxy-PEG-amine 
(MW 5 kDa) and methoxy-PEG-ethylamine (MW 20 kDa) were purchased from 
Jenkem Technology (Allen, TX) and NOF Corporation (Tokyo, Japan), respectively. 
1-Ethyl-3-(3- dimethylaminopropyl) carbodiimide HCl (EDC), N-
hydroxysuccinimide (NSH), 2-(N-morpholino) ethanesulfonic acid (MES) buffer, and 
side-A-lyzer dialysis cassettes were purchased from Thermo Fisher Scientific Inc. 
(Rockford, IL). Aqueous non-radioactive cell proliferation assay kit (MTS) was 
purchased from Promega (Madison, WI). Human umbilical vein endothelial cells 
(HUVEC) were purchased from the American Type Culture Collection (ATCC) and 
cultured according to ATCC protocols. F-12K medium was purchased from 
Mediatech Inc (Manassas, VA). Dialysis membranes were purchased from Spectrum 
laboratories Inc. (Rancho Dominguez, CA) All other chemicals are reagent grade and 
were used as received. 
4.2.2 Synthesis of carboxymethyl dextran sulfate (CMDS) 
CMDS was synthesized as described elsewhere.30-31 Briefly, DS (0.072 
mmole) was dissolved in ultrapure water. NaOH (2.5 mmole) was added to the 
solution, isopropanol (IPA) was then added followed by monochloroacetic acid (20 
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mmole). The reaction solution was stirred at 240 rpm and 60 oC for 3 h and then 
dialyzed against ultrapure water for 3 days (molecular weight cut off (MWCO) 1000 
Da). The dialyzing water was changed periodically. The product in the retentate was 
lyophilized. 
4.2.3 Synthesis of dextran sulfate-PEG 5 kDa and 20 kDa 
 Methoxy-PEG-amine (MW 5 kDa) was conjugated to CMDS via carbodiimide 
chemistry. Briefly, methoxy-PEG-amine (2.5 mole) was dissolved in PBS (pH 7.4). 
CMDS (10 mole) was dissolved in MES buffer (pH 6). EDC (50 mole) was added 
to the solution, followed by NHS (60 mole), and the solution was stirred for 15 min. 
2-Mercaptoethanol was added to produce a final concentration of 20 mM. Methoxy-
PEG-amine in PBS was then added to the solution. The reaction solution was stirred 
for 20 h at room temperature and subsequently dialyzed against ultrapure water for 3 
days (MWCO 6-8 kDa) and 1 day (MWCO 12-14 kDa). The product in the retentate 
was lyophilized and characterized. 1H-NMR (500 MHz, D2O): 3.30 ppm PEG CH3-O-
, 3.4-3.63 ppm dextran methylene, 3.54 ppm PEG O-CH2-CH2-. 
13C-NMR (500 MHz, 
D2O): 42.64 ppm PEG –NH-CH2-, 56-58 ppm dextran tetrahydropyran –CH-, 69.53-
70.93 ppm dextran methylene and PEG O-CH2-CH2-. FTIR: 3450, 2875, 1750 cm
-1.  
Methoxy-PEG-ethylamine (MW 20 kDa) was conjugated to CMDS using the 
same procedure except for the MWCO of the dialysis membrane used (12-14 kDa). 
1H-NMR (500 MHz, D2O): 3.30 ppm PEG CH3-O-, 3.4-3.63 ppm dextran methylene, 
3.54 ppm PEG O-CH2-CH2-. 
13C-NMR (500 MHz, D2O): 42.64 ppm PEG –NH-CH2-, 
56-58 ppm dextran tetrahydropyran –CH-, 69.53-70.93 ppm dextran methylene and 
PEG O-CH2-CH2-. FTIR: 3450, 2875, 1750 cm
-1.  
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4.2.4 Synthesis of pentosan sulfate-PEG 5 kDa and 20 kDa 
 PPS solution for injection was dialyzed against ultrapure water for 3 days 
(MWCO 1000 Da) followed by lyophilization. Methoxy-PEG-amine (MW 5 kDa) 
and methoxy-PEG-ethylamine (MW 20 kDa) were conjugated to PPS using the 
carbodiimide reaction as described above. The reaction solution was then dialyzed 
against ultrapure water for 3 days (MWCO 6-8 kDa) and 1 day (MWCO 12-14 kDa) 
for PEG5 conjugates. PEG20 conjugates were dialyzed for 3 days (MWCO 12-14 
kDa). The product in the retentate was lyophilized and characterized. 
PPS-PEG 5 kDa 1H-NMR (500 MHz, D2O): 3.30 ppm PPS -CH3, 3.35, 3.60 
ppm PPS –CH2- and PEG O-CH2-CH2, 5.68, 5.92 ppm PPS –CH2-. 
13C-NMR (500 
MHz, D2O): 14.4 ppm PPS –CH3, 42.73 ppm, PEG –NH-CH2-, 58.8 ppm PPS –CH3, 
72.3-72.6 ppm PPS –C- tetrahydropyran, 74.4 ppm PPS –CH2- and PEG O-CH2-CH2-
, 99.48 ppm PPS –C- tetrahydropyran. FTIR: 3450, 2875, 1750 cm-1.   
 PPS-PEG 20 kDa 1H-NMR (500 MHz, D2O): 3.30 ppm PPS -CH3, 3.35, 3.60 
ppm, PPS –CH2- and PEG O-CH2-CH2, 5.68, 5.92 ppm PPS –CH2-. 
13C-NMR (500 
MHz, D2O): 14.4 ppm PPS –CH3, 42.73 ppm PEG –NH-CH2-, 58.8 ppm PPS –CH3, 
72.3-72.6 ppm PPS –C- tetrahydropyran, 74.4 ppm PPS –CH2- and PEG O-CH2-CH2-
, 99.48 ppm PPS –C- tetrahydropyran. FTIR: 3450, 2875, 1750 cm-1.   
4.2.5 Characterization of polyanion conjugates 
 1H nuclear magnetic resonance (NMR) and 13C NMR spectra were recorded 
on a Bruker Avance AV-III 500 spectrometer. Fourier transform infrared (FTIR) 
spectra were obtained with a Perkin Elmer 100 FTIR spectrometer employing a 
universal ATR sampling accessory in the range of 4000-650 cm-1.  
Size exclusion chromatography (SEC) was carried out with a Shimadzu LC-
2010C HT equipped with a low temperature-evaporative light scattering detector 
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(ELSD-LT II) (Columbia, MD). The detector temperature was set at 50 oC. A Shodex 
OH pak SB 806 HQ column was used with ammonium acetate buffer pH 5 as eluent 
at a flow rate of 0.8 mL/min. The column temperature was kept constant at 40 oC. 
Various PEG standards, hyaluronic acid (HA), dextran, and DS were used as controls. 
The purity of the conjugates was determined by peak area percent. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
used as a second method to determine the electrophoretic mobility of conjugates. 
SDS-PAGE was performed using NuPAGE 4-12 % Bis-Tris Gels and NuPAGE Tris-
acetate SDS running buffer (Invitrogen, Carlsbad, CA). PEG standard and sample 
solutions were mixed with sample loading buffer and loaded onto the gel. The gel was 
electrophoresed at 130 mV for 40 min. After electrophoresis, the gel was fixed and 
stained at room temperature as described previously.32-34 Briefly, the gel was soaked 
in a 5 % glutaraldehyde solution for 15 min and immersed in 0.1 M perchloric acid 
for 15 min. The gel was then stained with barium iodine (a mixture of 5 % barium 
chloride and 0.1 M iodine solution at a ratio of 5:2 (v/v)). The gel was photographed 
using a densitometer (AlphaImager 2000, San Leonardo, CA). 
UV-VIS spectroscopy was used as a means to indirectly determine the 
numbers of PEG chains on conjugates by quantifying the amount of associated 
polyanion. Electrostatic interactions between sulfated polysaccharides and methylene 
blue molecules modified the visible spectrum of methylene blue. Therefore, these 
spectral changes could be used to quantify the amount of sulfated polysaccharides in 
unknown samples or to study the interactions of the two molecules.  This method is 
described elsewhere.35-37 Brieftly, polyanion conjugates were dissolved and diluted to 
optimal concentrations (1-21 g/mL). Methylene blue solution (0.07 mg/mL, 150 L) 
was added to polyanion conjugate solution (100 L) and mixed. After 5-15 min of 
116 
mixing, water (1.5 mL) was added. The depletion of methylene blue absorbance at 
664 nm was used to quantify the amount of polyanion on conjugates. PPS and DS 
were used as standards. The amount of conjugated PEG was obtained by subtracting 
the amount of polyanion from the total conjugate weight. 
4.2.6 Cytotoxicity assay 
 The cytotoxicity of polyanions and PEGylated polyanions was determined 
using a CellTiter 96 AQueous Cell Proliferation assay kit. HUVEC were seeded in 96-
well plates (8,000 cells/well) for 24 h prior to use. The growth medium was replaced 
with serum-free medium containing polyanions and PEGylated polyanions at various 
concentrations and incubated for 24 h. After incubation, the medium containing 
sample was replaced with 100 L of serum-free medium. Then, 20 μL of the mixture 
of MTS ([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium]) and PMS (phenazine methosulfate) was added to each 
well, and the plates were incubated at 37 oC, 5 % CO2 for 2 h. The absorbance of the 
formazan product was measured at 490 nm using a microplate reader (SpectraMax 
M5; Molecular Devices Corp., CA).  
4.2.7 Formulation of KGF-2:polyanion complexes 
 KGF-2 was aliquoted and stored at -80 oC. Prior to use, KGF-2 was thawed 
and dialyzed in PBS buffer overnight using a dialysis cassette (MWCO 10 kDa). The 
concentration of KGF-2 was determined by UV spectroscopy using extinction 
coefficient. The extinction coefficient of the protein is 35360 M-1 cm-1. PEGylated 
polyanions tested included PPS-PEG5, PPS-PEG20, DS-PEG5, and DS-PEG20. PPS 
and DS were used as controls. To prepare KGF-2:polyanion complexes, KGF-2 and 
polyanions were diluted with citrate phosphate buffer (20 mM, pH 6.2, 100 mM 
NaCl) to desired concentrations to produce the molar ratios and proper final protein 
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concentrations needed for each instrument. KGF-2 was mixed with polyanions or 
conjugates at 4 different molar ratios (e.g. KGF-2:polyanions or conjugates = 1:2, 1:1, 
2.4:1, and 6:1) throughout the studies unless otherwise noted. The protein solution 
was added into the polyanion solution slowly while stirring at 800 rpm. The mixture 
was stirred for 30 minutes prior to analysis. 
4.2.8 Physical characterization of KGF-2 complexes 
All experiments were conducted in 20 mM citrate phosphate buffer (pH 6.2, 
100 mM NaCl). This system was chosen because it was reported to provide sufficient 
solubility and stability of the protein.20 KGF-2 alone was used as a control in all 
studies.  
Far-UV Circular dichroism (CD) spectra were obtained with a Jasco-810 
spectropolarimeter equipped with a peltier temperature controller (Tokyo, Japan). The 
samples contained a final KGF-2 concentration of 0.2 mg/mL in a 0.1 cm path length 
cell. Spectra over a wavelength range of 200-250 nm were collected at 10 oC. The 
spectra were collected at a scan rate of 10 nm/min, a resolution of 0.5 nm, a response 
time of 4 s, and a bandwidth of 1 nm. In temperature-dependent studies, the thermal 
unfolding of KGF-2 and KGF-2 complexes were monitored at 229 nm over a 
temperature range of 10-85 oC in increments of 0.5 oC at a temperature ramp rate of 
1.5 oC/min and an incubation time of 120 s.  
 Intrinsic tryptophan fluorescence experiments were performed with a PTI 
QM-1 spectrofluorometer equipped with a four position peltier thermostated cuvette 
holder (Brunswick, NJ). An excitation wavelength of 295 nm (> 95% Trp emission) 
was used for simultaneously measuring both static light scattering and intrinsic 
tryptophan fluorescence. The emission spectra over a range of 300 to 400 nm were 
recorded at a 1 nm/s collection rate. A second photomultiplier placed at 180o to the 
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emission detector was used to record light scattering. Data were collected every 2.5 
oC from 10 to 85 oC with 180 seconds of thermal equilibrium at each temperature. A 
final KGF-2 concentration of 0.2 mg/mL was used. Fluorescence intensity and peak 
positions were obtained by a mean spectral center of mass method, after buffer 
subtraction. This method results in peak positions shifted by about 10 nm, but yields a 
better signal to noise ratio and increased reproducibility. Data analysis was performed 
using Felix (PTI) and Microcal Origin (V 7.0) software. 
 Differential scanning calorimetry (DSC) was performed with a VP-capillary 
DSC system (MicroCal Inc, Northampton, MA) equipped with an autosampler. 
Samples at a final KGF-2 concentration of 0.4 mg/mL were loaded in a 96-well plate 
and stored at 4 oC in a temperature controlled chamber prior to examination. 
Thermograms were obtained by increasing temperature from 5 to 80 oC with a 
ramping rate of 1 oC/min, a pre-scan equilibration time of 10 min and a filtering 
period of 16 s. Data were analyzed using Origin software after buffer subtraction. Tm 
values were selected using a multiple-state model in Microcal Origin software 
provided with the instrument. 
Heat induced aggregation was monitored by changes in optical density at 350 
nm using a Varian® UV-Visible spectrophotometer (Walnut creek, CA) over a 
temperature range of 20-90 oC. Changes in hydrodynamic diameters were obtained 
using dynamic light scattering (DLS) (DynaPro plate reader, Wyatt Technology, 
Santa Barbara, CA) over a temperature range of 10-65 oC. The observed 
hydrodynamic diameter was obtained using multi-component analysis function (based 
on mass). Final concentrations of KGF-2 used in both experiments were 0.05 mg/mL. 
Isothermal titration calorimetry (ITC) was used to monitor enthalpy changes 
resulting from the binding of KGF-2 to polyanions or conjugates (Microcal VP-ITC 
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calorimeter, MicroCal Inc, Northampton, MA) with a reaction cell volume of 1.45 
mL. KGF-2 (15-20 M) in the cell was titrated with polyanions or conjugates (170-
500 M) every 3-4 min at 25 oC with ~ 8 L injection volumes and ~ 25-30 total 
injections with stirring at 300 rpm. All solutions were degassed prior to use. Control 
titrations were performed to obtain heats of dilution which were subtracted from the 
corresponding heats of binding. 
4.3 Results 
 DSC was initially used to screen for the ability of several polyanions to 
increase the thermal stability of KGF-2. Polyanions tested include chromotropic acid 
(320 Da), acid fuchsin (585 Da), pyridoxal-phosphate-6-azophenyl-2′,4′-disulfonate 
(PPADS, 599 Da), congo red (699 Da), trypan blue (873 Da), PPS (5,000 Da), and DS 
(5,000 Da)  (Figure 4.2). PPS and DS were chosen because of their superior 
performance in enhancing the thermal stability of KGF-2 (see below). DS was 
modified to CMDS to make it amenable to PEG conjugation. PPS and CMDS were 
then covalently attached to two different amine-PEGs (5 and 20 kDa) via the 
carbodiimide reaction. A solution mixture of methoxy PEG (mPEG) (6 kDa) and 
KGF-2 was also tested using DSC, CD and fluoresce spectroscopy. Data showed that 
mPEG alone did not alter KGF-2 structure or increase the thermal stability of KGF-2 
(data not shown).  
4.3.1 Synthesis and characterization of polyanion-PEGs 
Different polyanion-PEGs were synthesized and extensively purified by 
dialysis. The conjugates were characterized by 1H NMR, 13C NMR, FTIR, and UV-
VIS spectroscopy. 1H NMR, 13C NMR, and FTIR showed characteristic peaks from 
both the polyanions and PEG. The yield of different polyanion conjugates ranged 
from ~54-88 % (Table 4.1). The yield of PPS-PEG5 and DS-PEG5 conjugates (~54- 
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Figure 4.2. DSC thermograms of KGF-2 and KGF-2:polyanion complexes at 
different molar ratios for (A) chromotropic acid (B) acid fuchsin (C) pyridoxal-
phosphate-6-azophenyl-2′,4′-disulfonate (PPADS) (D) congo red (E) trypan blue (F) 
PPS and (G) DS (upward = endothermic). 
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Table 4.1. Characteristics of polyanion conjugates 
 
Compound Actual yield (%) Purity (%)* 
 PEG/ polyanion 
(molar ratio)** 
Estimated MW 
(Da) *** 
PPS-PEG5 65.4 ~ 92 1.0  0.5 10,000 
PPS-PEG20 88.7 ~ 92 0.8  0.1 25,000 
DS-PEG5 53.8 ~ 97 5.0  0.8 30,000 
DS-PEG20 84.5 ~ 95 2.3  0.5 45,000 
 
*   Calculated from SEC peak areas.  
** Average  SD from two different syntheses. 
** and *** Obtained from methylene blue experiments. 
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65 %) was generally lower than that of PPS-PEG20 and DS-PEG20 conjugates (~84-
89 %).  
Conjugates were analyzed using SEC to assess product purity and relative 
size. PEG standards and HA polymers exhibited a linear relationship between MW 
and retention time (Figure 4.3 A). HA polymers, bearing carboxylate, hydroxyl, and 
acetyl groups, were eluted earlier than PEG standards possibly due to self-
association.38 Highly sulfated PPS and DS appear to interact with the column and 
were eluted much later (~17 min) regardless of their MW. Dextran bearing mainly 
hydroxyl groups was eluted sooner than DS. The apparent MW of PPS-PEG5 and DS-
PEG5 appeared to be < 3 kDa, while the MW of PPS-PEG20 and DS-PEG20 
appeared to be between 12-21 kDa when calculated using a linear regression equation 
for the PEG standard curve (Figure 4.3 A). These apparent MWs were inaccurate due 
to polyanion interaction with the column. The data indicated high purity (~92-97 %) 
of the conjugates as calculated from peak areas (Table 4.1 and Figure 4.3 B and C).  
The retention profile also suggested that the PPS and DS conjugates were primarily a 
single species with the exception of DS-PEG5 which manifested two populations.  
SDS-PAGE was employed as a second means to estimate the relative MW of 
the conjugates. Different PEG standards (7, 12, 21, and 66 kDa) were used as 
references.  The electrophoretic mobility of conjugates through polyacrylamide was 
strongly influenced by the electrical field (Figure 4.4). The negatively charged 
conjugates migrated much faster than the PEG standards due to the high charge 
density of the polyanion moieties. 
The number of PEG chains in the conjugates was quantified indirectly using 
the reduction of methylene blue absorbance at 664 nm upon binding to polyanions  
 
123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Size exclusion chromatography showed (A) polymers with different MW, 
structure, and charge exhibiting different retention times (numbers indicate MW 
(kDa)) (B) Chromatograms of PPS and PPS-conjugates and (C) chromatograms of DS 
and DS-conjugates. 
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Figure 4.4. SDS-PAGE analysis of polyanions and conjugates compared to PEG 
standards. 
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Figure 4.5. (A) The depletion of methylene blue absorbance (664 nm) upon binding 
with increasing amount of polyanions and (B) standard curves of PPS and DS. 
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(Figure 4.5 A). Standard curves were fit by linear regression with r2 = 0.9972 and 
0.9814 for PPS and DS, respectively (Figure 4.5 B). The number of polyanions in the 
conjugates was calculated from these linear regression equations. The amount of PEG 
was calculated by subtracting the amount of PPS or CMDS from the total conjugate 
weight. These experiments were carried out twice using materials from two different 
syntheses. PPS conjugates each contained one PEG chain per molecule as expected, 
whereas DS-PEG5 and DS-PEG20 conjugates had an average of 5 and 2 PEG chains 
per molecule, respectively (Table 4.1). The estimated MW of conjugates shown in 
Table 1 was used to estimate molar ratios throughout the remaining studies. 
4.3.2 Cytotoxicity test 
 The cytotoxicity of polyanions and conjugates was determined with HUVEC. 
PPS, DS, and their conjugates showed negligible cytotoxicity, whereas PEI (highly 
cytotoxic agent) exhibited notably low cytotoxicity (IC50 ~2 g/mL) (Figure 4.6). 
4.3.3 Differential scanning calorimetry 
 DSC was employed to measure the thermal unfolding of KGF-2 and KGF-2: 
polyanion complexes by monitoring the heat absorbed during unfolding of the protein. 
KGF-2 alone showed an endothermic peak beginning at ~35 oC with complete 
unfolding by ~53 oC. The transition melting temperature (Tm) was ~46 
oC as 
determined using a non two-state model. The presence of polyanions and conjugates 
significantly increased the transition temperature of KGF-2 suggesting they enhanced 
the thermal stability of the protein. For KGF-2:PPS complexes at 1:2 and 1:1 molar 
ratios, complexes showed a single transition peak and higher transition temperature 
(~60-62 oC) (Figure 4.7 A1 and 2). KGF-2:PPS complexes revealed a small leading 
shoulder at 1:1 molar ratio and started to show two transition peaks (~47 and ~60 oC) 
at 2.4:1 and 6:1 molar ratios (Figure 4.7 A3 and 4). KGF-2:PPS-PEG5 and KGF- 
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Figure 4.6. Cytotoxicity of (A) PPS and (B) DS and polyanion conjugates in HUVEC 
compared to PEI. 
 
 
 
 
 
128 
2:PPS-PEG20 complexes maintained single transition peaks at 2.4:1 molar ratios, but 
displayed two transition peaks (~47-53 and ~60 oC) at 6:1 molar ratios (Figure 4.7 A3 
and 4). KGF-2:DS and KGF-2:DS-PEG5 complexes maintained single transition 
peaks (~61-63 oC) at 1:2, 1:1, and 2.4:1 molar ratios, but showed two transition peaks 
(~46-49 and ~58-61 oC) at a 6:1 molar ratio (Figure 4.7 B1 to B4). KGF-2:DS-PEG20 
complexes appeared to possess single transition peaks at all molar ratios (~57-60 oC) 
except for the 6:1 ratio. 
4.3.4 Circular dichroism 
The secondary structure of KGF-2 in the presence and absence of polyanion-
PEGs was examined using far-UV CD. KGF-2 alone showed a minimum around 206-
208 nm and a maximum around 228-230 nm (Figure 4.8). This CD pattern is typical 
of proteins that share β–trefoil structure such as FGF-1 and FGF-2, interleukin-1, and 
hisactophillin.39-40 The complexes maintained similar CD spectra compared to free 
KGF-2 spectra at 1:2, 1:1, and 2.4:1 molar ratios, but displayed changes in intensity 
and positive peak wavelength position shifts (red shifts, 2-3 nm) (Figure 4.8 A1-A3 
and B1-B3). This probably reflected changes in secondary structure upon binding to 
polyanions or conjugates or is due to absorption flattening. The complexes at the high 
protein ratio (6:1 molar ratio) demonstrated analogous spectra to that of free KGF-2 
indicating that free KGF-2 was dominant in these systems (Figure 4.8 A4 and B4). To 
differentiate changes in secondary structure seen above, KGF-2 was unfolded by 
incubating in 4 M urea and 6 M guanidine HCl for 2 h. CD spectra of the unfolded 
protein showed reduction in intensity and blue shifts of positive peak wavelength 
positions (~5 nm) (Figure 4.9A). 
The effect of temperature on the secondary structure of KGF-2 in the presence 
of various polyanions and polyanion-PEG conjugates was monitored by changes in  
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Figure 4.7. DSC thermograms of KGF-2 and KGF-2:polyanion complexes at 
different molar ratios for (A) PPS and (B) DS and polyanion conjugates (upward = 
endothermic). 
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Figure 4.8.  Far-UV CD spectra of KGF-2 and KGF-2:polyanion complexes at 
different molar ratios (scanned at 10 oC) for (A) PPS and (B) DS and polyanion 
conjugates. 
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Figure 4.9.  (A) Far-UV CD spectra of unfolded KGF-2 (scanned at 10 oC) (B) 
melting curves of unfolded KGF-2 by monitoring fluorescence emission maximum 
position shifts. 
 
 
 
 
 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10.  Effect of temperature on the molar ellipticity of KGF-2 and KGF-
2:polyanion complexes (monitored at 229 nm) at different molar ratios for (A) PPS 
and (B) DS and polyanion conjugates. 
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CD ellipticity at 229 nm (Figure 4.10). CD measurements showed a thermal transition 
at ~39 oC for KGF-2 alone determined by a sigmoidal fit of the data. Complexes at 
some molar ratios showed higher melting temperatures, for example, KGF-2:PPS (1:2 
and 1:1 ratios, ~51-52 oC),  KGF-2:PPS-PEG5 (1:1 ratio, ~50 oC), KGF-2:PPS-
PEG20 (1:2, 1:1 and 2.4:1 ratios, ~50-52 oC),  KGF-2:DS (1:2 ratio, ~51 oC), KGF-
2:DS-PEG20 (1:1 and 2.4:1 ratios, ~48-50 oC). Some complexes manifested low to 
intermediate thermal stability enhancement such as KGF-2:PPS (2.4:1 and 6:1 ratios, 
~42-44 oC),  KGF-2:PPS-PEG5 (2.4:1 and 6:1 ratios, ~41-44 oC),  KGF-2:PPS-
PEG20 (6:1 ratio, ~42 oC), KGF-2:DS (1:1, 2.4:1, and 6:1 ratios, ~42-45 oC).  
Interestingly, KGF-2:DS-PEG5 complexes showed low to intermediate stability 
enhancement at all molar ratios. 
4.3.5 Intrinsic tryptophan fluorescence spectroscopy 
The effect of polyanions and conjugates on the physical stability of KGF-2 
was further explored using intrinsic tryptophan fluorescence spectroscopy. The 
observed emission maximum of KGF-2 was ~350 nm. This emission maximum was 
constant from 10-32 oC suggesting no change in the microenvironment of tryptophan 
residues. Upon further heating, a blue shift (7 nm) in the emission wavelength was 
observed suggesting that the Trp residues were less solvent-exposed. This was 
probably due to aggregation. After binding to polyanions or conjugates, the emission 
maximum positions at 10 oC were slightly shifted (blue shift, 1-4 nm) indicating 
subtle changes in the tertiary structure of KGF-2. In contrast, unfolded KGF-2 
displayed red shifts (4 nm) of the emission maximum positions at 10 oC and no 
transition temperature upon further heating (Figure 4.9B).  Binding to polyanions or 
conjugates increased the transition temperature of KGF-2 by 7-11 oC. Generally, more  
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Figure 4.11. Effect of temperature on the fluorescence emission maximum positions 
of KGF-2 and KGF-2:polyanion complexes at different molar ratios for (A) PPS and 
(B) DS and polyanion conjugates. 
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Figure 4.12. Effect of temperature on light-scattering intensity (monitored at 295 nm) 
of KGF-2 and KGF-2:polyanion complexes at different molar ratios for (A) PPS and 
(B) DS  and polyanion conjugates. 
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polyanion (e.g. 1:2 molar ratio) yielded greater thermal stability. PPS conjugates 
showed superior performance compared to DS conjugates (Figure 4.11). Once again, 
KGF-2 complexes at the 6:1 molar ratio had transition temperatures similar to that of 
KGF-2 alone indicating free KGF-2 was dominant in these formulations. 
Light-scattering experiments (295 nm) conducted simultaneously with 
intrinsic fluorescence experiments further confirmed the previously observed 
transition temperatures (Figure 4.12).  At low temperature, most KGF-2 complexes 
scattered more light than free KGF-2 in solution. The scattered light from complexes 
decreased as temperature increased. The onset of aggregation was apparent from a 
dramatic increase in scattered light, which peaked and then dropped as protein 
ultimately precipitated out of solution.  
4.3.6 Heat induced aggregation studies 
 Based on thermal stability studies, formulations that showed superior 
performance were selected for further aggregation studies. The turbidity of various 
formulations was monitored at 350 nm to determine the colloidal stability of the 
complexes. KGF-2 alone showed an onset of aggregation at ~47 oC, whereas KGF-2 
complexes exhibited higher onset temperatures (5-13 oC) (Figure 4.13 A). The slight 
turbidity of complexes at low temperature again indicated binding of the protein and 
PEG-polyanion. KGF-2:DS-PEG5 (1:2) showed a higher degree of turbidity and 
poorer colloidal stability compared to the other formulations. 
 The hydrodynamic diameter of the complexes was examined using DLS at 10 
oC (Table 4.2). KGF-2 complexes (17-79 nm) were larger than KGF-2 alone (~3 nm) 
as expected. The hydrodynamic diameter of the KGF-2 complexes with PPS:PEG20 
(79 nm) were larger than that of KGF-2 complexes with PPS:PEG5 and PPS (17 and 
24 nm, respectively). The hydrodynamic diameter of the KGF-2 complexes with DS,  
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Figure 4.13. Temperature induced aggregation of KGF-2 and selected KGF-
2:polyanion complexes monitored using (A) optical density (OD) at 350 nm and (B) 
dynamic light scattering (DLS). 
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Table 4.2. The hydrodynamic diameter of KGF-2 and selected KGF-2 complexes at 
10 oC 
 
Complexes Hydrodynamic diameter 
(nm)  SD 
Polydispersity 
 
KGF-2 3.3  0.2 0.26 
KGF-2:PPS (1:1) 23.6  9.9 0.20 
KGF-2:PPS-PEG5 (1:1) 17.4  3.8 0.27 
KGF-2:PPS-PEG20 (1:1) 79.0  23.8 0.26 
KGF-2:DS (1:1) 63.3  24.0 0.34 
KGF-2:DS-PEG5 (1:2) 68.8  17.9 0.37 
KGF-2:DS-PEG20 (1:1) 53.9  18.1 0.43 
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Figure 4.14. The hydrodynamic diameter of KGF-2:PPS-PEG20 complexes at 20 oC. 
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Table 4.3. Transition midpoint of KGF-2 alone and in the presence of polyanions and 
polyanion-PEGs 
 
  
 
Transition midpoint, Tm (
oC) 
 
Samples 
Molar  
ratios 
Circular 
dichroism 
(CD)* 
Intrinsic 
fluorescence* 
Differential 
scanning 
calorimetry 
(DSC)* 
     
KGF-2 - 39.2 42.5 45.7 
     
     
KGF-2:PPS (1:2) 51.8 52.5 62.0 
 (1:1) 51.3 49.3 60.3 
 (2.4:1) 44.3 43.0 47.6, 59.8 
 (6:1) 42.0 42.2 47.6, 59.3 
     
     
KGF-2:PPS-PEG5 (1:2) 44.1 52.1 61.7 
 (1:1) 50.0 53.0 62.2 
 (2.4:1) 44.3 44.7 61.4 
 (6:1) 41.1 42.1 46.5, 60.9 
     
     
KGF-2:PPS-PEG20 (1:2) 52.0 50.4 59.8 
 (1:1) 51.1 52.4 60.6 
 (2.4:1) 50.5 53.8 61.7 
 (6:1) 42.5 42.2 52.8, 60.5 
     
     
KGF-2:DS (1:2) 51.0 45.0 61.7 
 (1:1) 45.0 53.8 62.8 
 (2.4:1) 43.0 43.2 60.9 
  (6:1) 42.5 42.5 49.0, 60.61 
     
     
KGF-2:DS-PEG5 (1:2) 46.1 47.1 56.8 
 (1:1) 42.5 41.9 57.4 
 (2.4:1) 41.0 40.0 57.9 
  (6:1) 41.0 41.2 46.0, 57.6 
     
     
KGF-2:DS-PEG20 (1:2) 46.5 49.4 56.8 
 (1:1) 50.1 50.4 58.4 
 (2.4:1) 48.2 52.0 60.3 
  (6:1) 41.4 42.3 60.1 
     
* Values are  0.5 oC 
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Figure 4.15. Representative ITC binding isotherm of KGF-2 (20 M) titrated with 
DS (500 M) at 25 oC. 
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Table 4.4. Thermodynamic parameters of most KGF-2 interactions with polyanions 
or conjugates using a two-site model and a one-site model for KGF-2:PPS-PEG20 
complexes (*G = H-TS, T = 298 K) 
 
 PPS PPS-PEG5 PPS-
PEG20 
DS DS-PEG5 DS-PEG20 
Enthalpy       
H1 (kcal/mol) -1.411.8 -15.05.0 -4.1 -15.46.0 -17.0 -17.3 
H2 (kcal/mol) -73.034.0 -47.81.1  -35.96.9 -18.11.5 -29.717.6 
       
Entropy       
TS1 (kcal/mol) 7.61.9 -4.94.7 5.5 -5.05.9 3.416.4 -8.1 
TS2 (kcal/mol) -64.734.1 -39.30.8  -26.87.6 -6.83.7 -22.219.6 
       
Free energy       
*G1 (kcal/mol) -9.00.1 -10.00.2 -9.6 -10.40.1 -8.8 -9.2 
*G2 (kcal/mol) -8.40.2 -8.40.1  -9.10.7 -7.5 -7.1 
       
Ka       
Ka1 (M
-1) 3.9E65.4E5 2.4E78.5E6 1.1E7 4.3E77.2E6 2.6E6 6.0E5 
Ka2 (M
-1) 1.5E65.6E5 1.6E62.5E5  6.2E65.9E6 3.3E5 1.8E52.4E5
       
Ligand/protein       
N1 1.60.4 0.30.0 0.3 0.50.2 0.40.1 0.50.0 
N2 0.20.1 0.30.0  0.40.2 0.40.2 0.50.1 
       
Protein/ligand       
1/N1 ~0.6 ~3.2 ~3.9 ~2.0 ~2.6 ~2.2 
1/N2  ~4.3 ~3.1  ~2.4 ~2.4 ~2.2 
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DS:PEG5 and DS:PEG20 were similar (63, 69 and 54 nm, respectively). When 
subjected to increasing temperature, KGF-2 alone had an onset temperature of 
aggregation of ~31 oC (Figure 4.13 B1 and 2). KGF-2:PPS-PEG20 and KGF-2:DS-
PEG20 complexes had higher onset temperature of aggregation (~45-50 oC) and 
maintained size better than other formulations. KGF-2:DS-PEG5 (1:2) showed poorer 
colloidal stability compared to the other formulations. 
 Additionally, the hydrodynamic diameters of KGF-2:PPS-PEG20 complexes 
were monitored over a wider molar ratio range to test whether oligomerization may be 
occurring (Figure 4.14). The hydrodynamic diameters of the complexes at 0.5 and 1 
molar ratios (PPS-PEG20:KGF-2) increased dramatically (~700-1,000 nm) suggesting 
high degree of oligomerization. When adding more conjugate, the complex size 
decreased to ~50 nm at 2 and 3 molar ratios. The complex size increased again to ~ 90 
and 160 nm at 8 and 40 molar ratios. 
4.3.7 Isothermal titration calorimetry 
Thermodynamic characteristics were determined for the binding of KGF-2 to 
various polyanions and conjugates using ITC (Table 4.4). A representative binding 
isotherm of KGF-2 (20 M) titrated with DS (500 M) at 25 oC is shown in Figure 
4.15. The integrated peak areas were fit to a two-site independent binding site model 
for most complexes (a one-site model for KGF-2:PPS-PEG20 complexes) and the 
resulting enthalpies of binding (H), binding constant (K), entropies of binding (TS) 
and binding stoichiometries (n) were calculated. The inverse of the binding 
stoichiometries yielded a value for the number of proteins bound per ligand. 
 All interactions of KGF-2 with polyanions or conjugates revealed significant 
negative enthalpies of binding (Table 4.4). This may be explained by favorable 
electrostatic contacts between negative charges of these ligands with positive charges  
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on the protein. Most binding events (except KGF-2:PPS (first binding site), KGF-
2:PPS-PEG20 and KGF-2:DS-PEG5) were entropically disfavored (negative TS 
values). The change in free energy was similar for all polyanions or conjugates. 
Moderate to strong binding constants were detected for all titrations with Ka values in 
the micromolar range. Observed stoichiometry values for PPS conjugates were 
variable, whereas the values for DS conjugates were quite consistent over duplicate 
runs. Approximately two to three and one to four molecules of KGF-2 were bound to 
DS-based and PPS-based ligands, respectively.  
4.3.8 Competitive binding study 
In an attempt to investigate the reversibility of the binding between polyanion 
conjugates and the protein, KGF-2:PPS-PEG5 and KGF-2:PPS-PEG20 complexes 
were challenged using heparin (14 kDa, 0.2 to 5.0 U) and were then subjected to 
electrophoresis (data not shown). The free protein and protein from complexes 
showed no differences in electrophoretic mobility. The protein may have lost the 
heparin-binding domain and released polyanion conjuagates under these conditions. 
4.4 Discussion 
Heparin and other polyanionic materials have been utilized to stabilize or 
enhance the activity of HBGFs or other proteins such as insulin.41 Middaugh et al. 
showed that heparin enhanced the thermal stability of FGF-1 and prevented low-pH 
unfolding.23 In a separate report from the same group, a variety of polyanions such as 
heparin, sucrose octasulfate (SOS) and inositol hexaphosphate also elevated the 
aggregation temperature of KGF-2.20 Another report from the same group showed that 
heparin enhanced the thermal stability of FGF-20.24 Giger et al. also reported that 
heparin was able to suppress insulin aggregation.41  
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Hence, the polyanions, PPS and DS, were conjugated with different molecular 
weight PEG polymers. The conjugation reactions exhibited moderate to high yield 
and the dialyzed products showed high purity. The conjugates were then characterized 
using variety of methods. The methylene blue experimental data indicated that there 
was one PEG chain on each PPS conjugate, while DS:PEG5 and DS:PEG20 
conjugates had up to 5 and ~2 PEG chains, respectively (Table 4.1). PPS has a single 
reactive carboxyl group, while DS has multiple hydroxyl groups that can be converted 
to reactive carboxyl groups. Conjugation of PEG to DS agrees with previous reports 
indicating that the grafting density decreased as the PEG chain length increased.42-43 
Higher MW PEGs have slower diffusion rates and greater excluded volume, thereby 
slowing transport to reaction sites and impeding tight packing compared to low MW 
PEGs.42  
In gas phase, it is difficult to ionize highly acidic compounds especially 
polysulfated materials or polysulfonic acids, since these compounds tend to tightly 
bind counterions such as Na+ and K+.44 Electrospray ionization (ESI) and matrix 
assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry 
were attempted to determine the MW of these conjugates, but the experiments were 
not successful even when employing special sample preparation methods.44-45 
Therefore, SEC and SDS-PAGE were chosen as methods to estimate the size of these 
conjugates. 
Based on SEC and SDS-PAGE data, the conjugates had narrow populations 
and exhibited characteristics of both PEG and the polyanion. Ideally, SEC systems 
should be calibrated with compounds having similar structures to the sample being 
analyzed. PEG, HA or dextran were not suitable standards for this system. 
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Furthermore, these sulfated polysaccharides interacted with the column of 
polyhydroxymethacrylate.  
 The effect of polyanions and conjugates on the structure and stability of KGF-
2 was studied using far-UV CD and intrinsic fluorescence to track both secondary and 
tertiary structure changes. The observed changes in CD spectra and emission 
maximum positions of bound KGF-2 suggested that the binding of polyanions or 
conjugates altered the secondary and tertiary structures of KGF-2. Structural changes 
upon binding with charged compounds have been commonly observed. For example, 
structural alteration as seen in parathyroid hormone (PTH) in the presence of DS (40-
50 kDa) or heparin (12-16 kDa) and FGF-1 upon binding with suramin.46-47  
The observed changes in CD spectra may have also been due to absorption 
flattening from oligomerization, which has been previously reported.46,48 The degree 
of oligomerization depended on the amount of polyanion present, which is consistent 
with data for KGF-2:PPS-PEG20 complexes reported here (Figure 4.14). At low 
polyanion to protein ratio (0.1), little or no oligomerization was observed. At higher 
ratios (0.5 and 1), the increase in hydrodynamic diameter suggested extensive 
oligomerization . At even higher ratios (2 and 3), the protein was probably saturated 
by polyanion resulting in small complexes. As a result, high polyanion to protein 
ratios were used in many studies including a 50-fold excess (w/w) of SOS to KGF-
2.20  
The apparent melting temperature of KGF-2 in the presence of polyanions and 
conjugates was, however, significantly increased by 11-13 oC, based on fluorescence 
and CD data. Polyanions probably stabilized KGF-2 by interacting with positively 
charged amino acid clusters on the surface of the native protein.49  
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Most polyanion or conjugate interactions with KGF-2 were enthalpically 
driven, however, some formulations showed entropically driven binding. In many 
situations, electrostatic bindings usually are entropically driven.  This is usually 
explained by the removal of water molecules from the charged compounds.47 There 
are, however, examples of electrostatic interactions between proteins and charged 
compounds that are enthalpically driven. For example, binding between gum arabic 
and BSA, between heparin and PTH, and between sodium dodecyl sulphate and 
gelatin.47,50-51  
The observed negative entropy values may be indicative of different 
interactions occurring in this system. Negative entropy may primarily be due to 
oligomerization. DLS data showed a drastic increase in size of the complexes at molar 
ratios of 0.5:1 and 1:1 (PPS-PEG20:KGF-2). Oligomerization may interfere with 
interactions between KGF-2 and polyanions and constrain their motions. Also, ITC 
data indicated multiple molecules of KGF-2 bound to a single chain of PPS or DS 
conjugate. Under these conditions, microaggregates may occur in which multiple 
proteins bind to extended polyanion chains, which can then oligomerize.47 In such 
cases, the thermodynamics of microaggregate processes may overlap with the 
observed thermodynamic binding parameters making interpretations difficult. Similar 
results have been reported by Mach and Middaugh with FGF-1 and other growth 
factors.46,48 Lastly, PEG may sterically hinder binding (e.g. DS-PEG5), which would 
reduce the magnitude of thermodynamic values associated with polyanion binding.  
Finally, ITC data also suggested that one to four molecules of KGF-2 were 
bound with PPS conjugates, whereas two to three molecules of KGF-2 were bound 
with DS conjugates. This agreed with a previous binding study between KGF-2 and 
DS (8,000 Da), which revealed that 2 to 2.6 KGF-2 molecules were bound to one DS 
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chain.53 The same study also indicated that heparin (5,000 Da):KGF-2 complexes 
were heterogeneous consisting of one to four KGF-2 molecules per complex.  
4.5 Conclusion 
Based on various spectroscopic and calorimetric methods, the polyanion 
conjugates appeared to increase the thermal stability of KGF-2. Conjugates with 
higher PEG densities (DS-PEG5) did not bind KGF-2 as well as other conjugates, 
thus reducing the stabilization effect. PEG MW did not have a noticeable effect. 
There are several important factors to consider if polyanion conjugates are used to 
produce more stable pharmaceutical formulation of KGF-2 including the 
identification of proper molar ratios to avoid oligomerization. Polyanion-PEG 
conjugates were validated as alternative excipients that can improve the stability of 
heparin-binding proteins and that may ultimately be explored to extend circulation 
half-life.  
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5.1 Summary and conclusions 
Polymeric drug delivery systems hold promise in the 21st century.  Polymers 
are versatile, easy to produce at the industrial scale, and amenable to conjugation 
reactions. Passively or actively targeted drug delivery has been made possible by 
using well-controlled size or by grafting targeting ligands to polymers.1-3 
Furthermore, pharmacokinetics, biodistribution, and/or therapeutic indexes of some 
drugs have been improved by PEGylation or by other types of polymer conjugation.4 
The increasing number of polymeric drugs commercially available or being evaluated 
in clinical trials demands an enhanced effort to produce innovative and more efficient 
polymers. 
In this thesis, we have explored the potential uses of some tailor-made 
polyelectrolytes in gene and protein delivery. In chapter 2, the cytotoxicity and 
transfection efficiency of a synthetic polyvinylamine (PVAm) nanogel was probed as 
a function of particle charge and degradability. We found that non-degradable 
nanogels with high charge densities yielded higher gene expression compared to 
nanogels with low charge densities. Interestingly, acid-labile nanogels with low 
charge densities yielded extended gene expression while maintaining lower 
cytotoxicity. The data reiterated that balancing transfection efficiency and toxicity is a 
key that should be further explored in order to develop suitable gene vectors. 
Furthermore, the data also suggested that gene expression studies should be extended 
for longer periods of time to account for delays in transfection or cell viability. 
Cationic nanoparticles have been reported to be cleared from the body quickly 
due to an increased hydrodynamic diameter resulting from serum protein adsorption.5 
Neutralization of the nanoparticle surface via PEGylation was shown to be effective 
in preventing serum protein adsorption.6 Therefore, the synthetic PVAm was replaced 
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with the biodegradable CPP TAT conjugated with PEG in an effort to improve plasma 
compatibility and ultimately, in vivo performance.  
Chapter 3 presented these PEGylated TAT/DNA complexes and explored 
targeted versions as a means to transfect ICAM-1 expressing cells. ICAM-1 
upregulation is associated with many diseases. TAT polyplexes with DNA have 
historically shown relatively poor gene delivery, but the transfection efficiency was 
enhanced by condensing TAT/DNA complexes to a small particle size using calcium. 
LABL peptide targeting ICAM-1 was conjugated to the TAT peptide using a PEG 
spacer. We found that PEGylation reduced the transfection efficiency of TAT as 
expected, but targeted TAT complexes formulated with an optimal calcium 
concentration regained much of the lost transfection efficiency in activated A549 cells 
(overexpressing ICAM-1). There are, however, several concerns about the use of this 
gene vector. Complexes were produced manually, thus batch to batch consistency will 
be of concern when conducting studies in animals. Although the targeted TAT 
complexes showed selectivity to ICAM-1 on activated cells, however these effects 
seem to be small. Therefore, it is necessary to compare the transfection efficiency 
between non-targeted and targeted formulations and, more importantly, placebo in an 
early in vivo screen. Lastly, dilution effect may hinder the targetability of these 
complexes when administered intravenously, hence local administration may be 
explored at an initial stage of animal trials. 
In chapter 4, another polyelectrolyte vehicle was explored for protein delivery. 
Electrostatic interactions between polyanions and several FGFs have been reported to 
enhance the thermal stability of these proteins as well as other ‘heparin-binding’ 
proteins. PEG was grafted to the polyanions, PPS and DS, as a novel means to non-
covalently PEGylate KGF-2. PPS-PEG and DS-PEG conjugates were able to stabilize 
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KGF-2 by increasing the melting temperature. It is possible that micro-aggregation 
occurs simultaneously with electrostatic binding when conducted ITC experiments. 
The thermodynamics of microaggregation may be superimposed upon the measured 
thermodynamic binding parameters making interpretations difficult. Therefore, 
alternative approaches such as analytical ultracentrifugation may be used to identify 
KGF2:polyanion conjugate stoichiometry. Also, acrylamide gel electrophoresis 
seemed not to be suitable to investigate the interaction affinity in this system, 
alternative approaches such as surface plasmon resonance may be used to elucidate 
the binding affinity. 
Furthermore, there are several concerns about the utilization of these 
conjugates. PEG may sterically hinder receptor binding affinity of the protein. In 
addition, polyanion conjugate binding may interfere the presentation of KGF-2 to 
their cell surface receptors, which may diminish signal transduction, thus receptor 
binding assays are needed. The observed structural changes upon binding may affect 
protein activity, mitogenic activity in fibroblast cells will be helpful to predict the 
activity of protein conjugates. 
However, these conjugates are encouraging excipients that can improve the 
stability of heparin-binding proteins based on this work and the generality of 
polyanions and protein interactions known from the literature.  
5.2 Future directions 
With respect to the continued development of targeted TAT/DNA complexes, 
the next key task is to evaluate the transfection efficiency of these complexes in 
primary human cells. Even though, the correlation between in vitro and in vivo 
efficiency of gene vectors has been elusive, the efficiency data from primary human 
cells will provide critical information for these complexes. In addition, 
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immunogenicity (cytokine and chemokine induction) and an early in vivo screen of 
antigenicity (e.g. IgG, IgM production) will be essential when evaluating transfection 
efficiency of these complexes in an animal model of human disease. It is worth noting 
that production of PEGylated TAT or targeted TAT complexes with DNA is 
laborious, therefore, production scale-up should be taken into consideration in order 
to transition from the laboratory bench to the clinic.  
To further develop PPS-PEG and DS-PEG conjugates, the next step should be 
to carry out preclinical pharmacokinetic and biodistribution tests in an animal model.  
This data will be crucial to determine whether key benefits of PEGylation are 
maintained by this electrostatic PEGylation approach. In addition, immunogenicity 
assays should be conducted in an animal model (e.g. mice) to monitor specific IgG 
levels. These should be explored for both polyanion-PEG conjugates and for protein 
complexes. In the next step of formulation development, short- and long-term stability 
tests of the protein and protein complexes in both solution and lyophilized forms 
should be explored. Furthermore, studies to find optimized reconstitution mediums or 
conditions will also be necessary to enhance the recovery of the protein.  
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